# Non-small-cell lung cancer

Source: https://onco.cc/cancers/nsclc/  
OnCo record `nsclc` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story.

## Summary

Biomarker testing (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C, HER2, PD-L1) is mandatory at diagnosis. Oncogene-addicted disease gets targeted therapy first (osimertinib, amivantamab-lazertinib, lorlatinib, selpercatinib, zongertinib, sotorasib/adagrasib); the rest get PD-(L)1 blockade ± chemotherapy. Perioperative immunotherapy (CheckMate 816, KEYNOTE-671) and adjuvant targeted therapy (ADAURA, ALINA) are standard. ADCs (Dato-DXd, T-DXd, telisotuzumab vedotin, iza-bren, HER3-DXd) and bispecifics (ivonescimab PD-1×VEGF) are the next layer. Low-dose CT screening cuts mortality by 20-24%.

How common it is. Non-small-cell disease is about 85 percent of lung cancer, so the world figures for the site are very close to the figures for this disease: 2,637,005 new lung cancers and 1,861,839 deaths a year, first in the world on both counts (GLOBOCAN 2024). GLOBOCAN does not split lung cancer by histology, so the split has to be read from registry series: of 1,572,045 lung cancers in men in 2022, 45.6 percent were adenocarcinoma, 29.4 percent squamous cell carcinoma and 6.5 percent large-cell carcinoma, and of 908,630 in women, 59.7, 17.1 and 6.5 percent, which is 81.5 percent of men's and 83.3 percent of women's lung cancers in the three non-small-cell types (Lancet Respiratory Medicine 2025). In the UK the site total is around 50,200 cases and 32,800 deaths a year (Cancer Research UK); in the United States 229,410 cases and 124,990 deaths are projected for 2026, with a five-year relative survival of 29.5 percent for the site (SEER).

Why the numbers are moving in opposite directions. In the United States lung cancer incidence is falling 1.9 percent a year and mortality 4.1 percent a year, the mortality falling faster than the incidence because more cancers are found early and because targeted drugs and immunotherapy work. In the UK incidence is down 11 percent since the early 1990s and mortality down 40 percent since the early 1970s, but the projection to 2038 to 2040 is for around 66,200 cases a year: rates fall while the population ages, so the count rises. What does not move is the share found late. In England 34 percent of staged cases in 2022 were stage I or II; in the United States 24 percent are localised at diagnosis, 21 percent regional and 51 percent already distant (Cancer Research UK; SEER).

Smoking, and how much of the disease it explains. This is an account of why the UK has as many lung cancers as it does, not of why any one person has one, and it changes nothing about the treatment on this page. Cancer Research UK attributes 72 percent of UK lung cancer cases to tobacco, 71 percent to active smoking and 1 percent to second-hand smoke, and about 86 percent of UK lung cancer deaths to smoking. Seventy-nine percent of UK cases are judged preventable in total. Stopping works and works better the earlier it happens: of British men who smoke all their lives 15.9 percent die of lung cancer by age 75, against 9.9 percent of those who stop by 60, 6 percent by 50, 3 percent by 40 and 1.7 percent by 30; in women the figures are 9.5 percent for lifelong smokers, 5.3 percent for stopping by 60 and 2.2 percent by 50. Risk in people who stopped about 7 years ago is 43 percent lower than in current smokers, and 72 percent lower about 12 years after stopping. Starting younger is worse: lung cancer death risk is 37 percent higher per five years younger at starting (Cancer Research UK, quoting the studies behind each figure).

The other causes, with the share of UK cases each accounts for. Workplace exposures account for 13 percent of UK cases, and asbestos alone is linked to 6 to 8 percent of UK lung cancer deaths each year, with lung cancer mortality 77 percent higher in asbestos-exposed workers than in the general population. Outdoor air pollution accounts for 8 percent of UK cases; adenocarcinoma risk is 40 percent higher per 10 micrograms per cubic metre of fine particulate matter, and overall lung cancer risk 9 percent higher, with no significant association for the coarser PM10 fraction. Ionising radiation accounts for 5 percent, of which indoor radon is the largest part: an estimated 9 percent of European lung cancer deaths are linked to indoor radon, and risk rises 16 percent per 100 becquerels per cubic metre of usual home radon. Second-hand smoke accounts for 1 percent of all cases but an estimated 15 percent of cases in people who have never smoked, raising their risk by 31 percent. Family history matters independently of smoking: risk is 82 percent higher with an affected sibling and 25 to 37 percent higher with an affected parent. Previous lung disease matters too, with risk 43 to 57 percent higher after pneumonia and 104 to 144 percent higher after emphysema. The smaller occupational exposures each account for a fraction of a percent of British cases: silica 0.02 percent, diesel engine exhaust 0.02 percent, painting 0.01 percent, welding 0.001 percent (Cancer Research UK).

Lung cancer in people who have never smoked. Fifteen percent of lung cancers diagnosed in the UK arise in never-smokers, which would make it the 8th commonest cancer in the country if it were counted as a disease of its own (BJC Reports 2023); worldwide the figure is put at 15 to 25 percent depending on the region, and if counted separately it would be the 7th commonest cause of cancer death (OLIVE protocol, BMJ Open Respiratory Research 2026; Health Science Reports 2026). It is a different disease: overwhelmingly adenocarcinoma, commoner in women and in east Asian populations, and far more often driven by a targetable mutation. The UK's largest prospective look at it, the Million Women Study, followed 634,039 never-smoking women for 14 years and found 1,469 lung cancers, 0.2 percent of the cohort; of 34 candidate risk factors only three reached significance, non-white ethnicity (relative risk 2.34), asthma requiring treatment (1.32) and height of 165 cm or more (1.16), and restricting the analysis to adenocarcinoma did not change the result. The practical consequence is that the risk factors that select people for screening do not select these patients, and the assumption that a non-smoker's cough is not cancer delays their diagnosis.

How it presents, and when the NHS refers. The NHS lists a cough that is not going away, shortness of breath, coughing up blood, chest or shoulder pain, repeated chest infections or one that will not clear, losing weight without trying, loss of appetite and constant tiredness as the common symptoms, and swelling of the face or neck, difficulty swallowing, a hoarse voice that does not go away and finger clubbing as the less common ones; early lung cancer often causes nothing at all. NICE NG12 turns that into three rules for general practice. Refer on the suspected cancer pathway if the chest X-ray suggests lung cancer, or if the person is 40 or over with unexplained coughing of blood (1.1.1). Offer an urgent direct access chest X-ray at 40 and over for two or more of cough, fatigue, shortness of breath, chest pain, weight loss and appetite loss, or for one of them in anyone who has ever smoked (1.1.2). Consider an urgent chest X-ray at 40 and over for persistent or recurrent chest infection, finger clubbing, supraclavicular or persistent cervical lymphadenopathy, chest signs consistent with lung cancer, or a raised platelet count (1.1.3). Mesothelioma has its own rules in the same section, with asbestos exposure lowering the threshold. In England in 2019 about 26 percent of lung cancers were diagnosed after an urgent suspected cancer referral and 33 percent after an emergency presentation (Cancer Research UK).

Screening: the evidence, the programme and the harms. The evidence is two randomised trials. The National Lung Screening Trial gave 53,454 Americans aged 55 to 74 with 30 or more pack-years three annual low-dose CT scans or chest radiographs and cut lung cancer mortality by 20.0 percent (95 percent confidence interval 6.8 to 26.7) and all-cause mortality by 6.7 percent. NELSON gave 13,195 men and 2,594 women aged 50 to 74 volume CT at baseline and years 1, 3 and 5.5, and found a lung cancer death rate ratio of 0.76 (0.61 to 0.94) in men at ten years, with only 2.1 percent of participants referred for a suspicious nodule. The number needed to screen to prevent one lung cancer death is 323 over 6.5 years in the National Lung Screening Trial and 130 over ten years in NELSON. The harms are real and are the reason screening is targeted rather than universal: 24.2 percent of low-dose CT screens in the National Lung Screening Trial were positive and 96.4 percent of those positives were false; false positives led to 17 invasive procedures per 1,000 people screened, with fewer than one major complication; incidental findings were reported in 4.4 to 40.7 percent of people screened; and estimates of overdiagnosis, the cancers found that would never have caused harm, ranged from 0 to 67 percent across studies (US Preventive Services Task Force evidence report, 2021). In the United States the Task Force recommends annual low-dose CT from 50 to 80 for people with a 20 pack-year history who smoke or stopped within the past 15 years (grade B, 2021), widened from the 55 to 80 and 30 pack-year criteria of 2013.

Screening in the United Kingdom. The UK National Screening Committee recommended targeted screening in June 2022 for people aged 55 to 74 identified as being at high risk, with smoking cessation built into the service, and named England's Targeted Lung Health Check programme as the starting point. The national programme was announced on 26 June 2023, costs £270 million a year at full size and is expected to deliver almost one million scans and find as many as 9,000 cancers a year. Eligibility is not age alone: a person's GP record identifies ever-smokers aged 55 to 74, and a risk model decides who is scanned, using PLCOm2012 or the Liverpool Lung Project version 2 in England, at a PLCOm2012 threshold of 1.51 percent risk over six years. Scanning is every two years for those at high risk. The first phase invited about 900,000 people, made 375,000 risk assessments, carried out 200,000 scans and found more than 2,000 cancers, of which 76 percent were early stage against 29 percent outside the programme in 2019, and about 70 percent of the scanning was done in mobile units parked in places such as supermarket car parks, deliberately in more deprived areas where people are four times more likely to smoke. By March 2025 the programme had invited over two million people and diagnosed 7,193 lung cancers, 63.1 percent at stage 1 and 12.6 percent at stage 2, and the early-stage share of all lung cancer in England rose over the five years, most in the most deprived regions. Full national coverage is expected in 2030.

Diagnosis and staging. NICE NG122 sets the order. Contrast-enhanced CT of the chest, including the liver, adrenals and lower neck, comes before any biopsy. Everyone who could have treatment with curative intent is offered PET-CT. Where the nodal stage would change treatment, nodes are sampled through the airway or oesophageal wall: endobronchial ultrasound-guided transbronchial needle aspiration, endoscopic ultrasound-guided fine-needle aspiration, or both, with surgical mediastinal staging kept for a negative result when suspicion remains high. Enlarged nodes (10 mm or more in short axis on CT) or other lesions are biopsied in preference to the primary when the nodal stage decides treatment. Brain imaging is staged to the stage: none for clinical stage 1 without neurological symptoms, where the prevalence of brain metastases is about 4 percent; contrast-enhanced brain CT for clinical stage 2; contrast-enhanced brain MRI for stage 3. Samples must be big enough for subtyping and molecular markers, and the panel to run is set by the National Genomics Test Directory rather than by the guideline. One caution a reader should know: NG122's recommendations were written against the 7th edition of the American Joint Committee on Cancer staging system, which NICE says on the page, while staging in the clinic has moved two editions on.

The ninth edition of TNM, in force since 1 January 2025. The International Association for the Study of Lung Cancer built a new database of 124,581 patients diagnosed between 2011 and 2019 and analysed 76,518 of them. The T descriptors were tested and left alone: they are identical to the eighth edition. The N descriptors changed, splitting N2 into N2a, a single ipsilateral mediastinal or subcarinal station, and N2b, multiple ipsilateral mediastinal stations with or without the subcarinal station. The M descriptors changed at the far end, splitting M1c into M1c1, multiple metastases in one extrathoracic organ system, and M1c2, multiple metastases in several organ systems; both stay in stage group IVB. The stage groups moved to follow: T1N1 to IIA, T1N2a to IIB, T3N2a to IIIA, and T2aN2b and T2bN2b to IIIB. The practical effect is finer prognostic separation at the borders of resectability rather than a change in who is operated on, and a discontinuity in every survival series that spans the change.

Pathology: how the histology is decided. The 2021 WHO classification keeps the same order of evidence: morphology first, immunohistochemistry to support it, molecular tests last. That matters because most lung cancers are diagnosed on a small biopsy or a cytology specimen rather than a resection, and the fifth edition added a section dedicated to classifying small samples for exactly that reason. In practice a poorly differentiated tumour is assigned by a two-stain panel: TTF-1 marks adenocarcinoma, p40 marks squamous cell carcinoma, and a tumour positive for one and negative for the other is called that type rather than left as non-small-cell carcinoma not otherwise specified, because the name decides whether the tumour is sequenced and whether pemetrexed and bevacizumab are safe. Other changes in the fifth edition bear on the corpus's pages: invasive non-mucinous adenocarcinomas are graded by the percentage of each growth pattern, only the invasive part counts towards the T size in part-lepidic tumours, spread through air spaces is recognised as a prognostic feature, lymphoepithelial carcinoma moved into the squamous cell carcinomas, and thoracic SMARCA4-deficient undifferentiated tumour was recognised as an entity.

Prevention. Because tobacco causes about 72 percent of UK cases, prevention is tobacco control and stopping smoking, and nothing else comes close. NICE NG209 covers the whole of it, from preventing uptake in people aged 24 and under to treating dependence in everyone aged 12 and over, and was last updated on 4 February 2025 to add recommendations on cytisinicline. Lung cancer screening is also a prevention service and not only a detection service: the UK National Screening Committee's recommendation was explicitly for screening with integrated smoking cessation, and the screening appointment reaches people who smoke at a moment when they will act. The other preventable exposures are radon, which can be measured in a home and reduced by sealing and ventilation, and workplace exposures to asbestos, silica, diesel exhaust and the rest, which are regulated rather than chosen.

## Fields

- Kind: Cancer
- Last checked: 2026-09-25
- Also known as: LUAD; LUSC; LSCC; TCGA-LUAD; TCGA-LUSC; lung adenocarcinoma (TCGA LUAD cohort); lung squamous cell carcinoma (TCGA LUSC and CPTAC LSCC cohorts); Non-small-cell lung cancer (adenocarcinoma, squamous, large cell); NSCLC; Non-small cell lung carcinoma; Non-small-cell carcinoma of the lung
- Tags: lung; spike
- Group: lung
- Burden: About 85 percent of lung cancer, and lung cancer is first in the world for both new cases and deaths: 2,637,005 cases and 1,861,839 deaths a year (GLOBOCAN 2024). Around 50,200 UK lung cancers and 32,800 UK deaths a year (Cancer Research UK); 229,410 US cases and 124,990 deaths projected for 2026, with five-year relative survival of 29.5 percent for the site (SEER). Of lung cancers in men worldwide 45.6 percent are adenocarcinoma, 29.4 percent squamous and 6.5 percent large-cell; in women 59.7, 17.1 and 6.5 percent (Lancet Respiratory Medicine 2025).
- Subtypes: Adenocarcinoma; Squamous; EGFR-mutant; ALK-rearranged; KRAS-mutant; PD-L1-high; Adenocarcinoma (~50%); Squamous cell carcinoma (~25-30%); Large-cell / NOS; EGFR-mutant (exon 19 del, L858R, exon 20 ins, uncommon); ROS1-rearranged; KRAS G12C and non-G12C; BRAF V600E; MET exon 14 skipping / MET-amplified; RET-fusion; HER2-mutant; NTRK-fusion; Driver-negative PD-L1-high (TPS ≥50%); Driver-negative PD-L1-low/negative; STK11/KEAP1 co-mutated (IO-resistant)
- Biomarkers: EGFR; ALK; ROS1; BRAF V600E; MET ex14 / amplification / c-MET IHC; RET; NTRK; KRAS G12C; HER2 mutation; PD-L1 TPS; ctDNA; PD-L1 TPS (22C3); EGFR (exon 19 del, L858R, exon 20 ins, T790M, C797S); ALK fusion; ROS1 fusion; KRAS G12C (and G12D/V); MET exon 14 skipping, MET amplification, c-Met IHC; RET fusion; HER2 (ERBB2) mutation; NTRK fusion; STK11 / KEAP1 (prognostic, IO resistance); TP53 / RB1 (transformation risk); ctDNA (genotyping, MRD, resistance tracking); TMB (limited use); TTF-1 and p40 immunohistochemistry to assign histology on a small biopsy before molecular testing; Spread through air spaces, recorded on resection specimens since the 2021 WHO classification; Pathological stage by TNM 9, including the N2a and N2b split; KRAS G12C: 41-51%; EGFR: 12-47%; EGFR exon 19 deletion: 13-19%; EGFR L858R: 9-21%; EGFR exon 20 insertion: 1-3%; STK11 (LKB1): 13-18%; KEAP1: 11-18%; MET exon 14 skipping: 2-4%; MET amplification: 2-3%; ERBB2 (HER2) mutation: 2-4%; BRAF V600E: 1-2%; ALK fusion: 3-6%; ROS1 fusion: 1-3%; RET fusion: 1-2%; NTRK fusion: 0.2%; NRG1 fusion: 0.3%

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/nsclc/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/nsclc/#overview [22 subtypes, 16 state-of-the-art points]
- Types and stages (own page): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/nsclc/what-it-is/ [42 subtypes, 7 staging notes, 6 sites of spread]
- Symptoms and diagnosis (own page): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/nsclc/finding-it/ [6 symptoms, 43 biomarkers, 55 prevalence rows]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/nsclc/#treating-it [16 settings, 12 regimens, 14 decisions with options]
- Trials and papers (own page): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/nsclc/evidence/ [709 trials, 165 trials in the subtypes, 127 key papers, 27 milestones]
- Biology and targets (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/nsclc/science/ [188 targets, 27 pathways, 14 preclinical models]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/nsclc/where-you-are/ [92 centres, 30 centres in the subtypes, 34 UK centres]
- Decisions and support (own page): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/nsclc/living-with-it/ [51 questions, 6 red cards, 1 decision aid]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/nsclc/coming/ [219 medicines, 6 medicines in the subtypes, 709 trials, 90 ideas, 20 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/nsclc/data/ [2098 connected records, 24 notes]

## Standard of care

- Screening (age 50-80, ≥20 pack-years): Annual low-dose CT with Lung-RADS reporting; AI nodule scoring emerging; robotic bronchoscopy for peripheral nodule biopsy. ([Low-dose CT lung screening](https://onco.cc/technologies/low-dose-ct-screening/), [NLST & NELSON (low-dose CT screening)](https://onco.cc/trials/nlst-nelson/), [Robotic and navigational bronchoscopy](https://onco.cc/technologies/robotic-bronchoscopy/), [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/))
- Stage I-II resectable: Lobectomy or segmentectomy (small peripheral) with nodal staging; SBRT if inoperable. Stage IB-IIIA: neoadjuvant chemo-IO (CheckMate 816) or perioperative chemo-IO (KEYNOTE-671); adjuvant osimertinib if EGFR-mutant (ADAURA), alectinib if ALK-positive (ALINA); adjuvant chemotherapy otherwise for stage II+. ([Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [CheckMate 816](https://onco.cc/trials/checkmate-816/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/), [ADAURA](https://onco.cc/trials/adaura/), [ALINA](https://onco.cc/trials/alina/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Alectinib](https://onco.cc/drugs/alectinib/))
- Stage III unresectable: Concurrent platinum chemoradiation → durvalumab 1 year (PACIFIC), or osimertinib until progression if EGFR-mutant (LAURA). Proton therapy in selected cases. ([IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [PACIFIC](https://onco.cc/trials/pacific/), [LAURA](https://onco.cc/trials/laura/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Proton therapy](https://onco.cc/technologies/proton-therapy/))
- Metastatic, EGFR exon 19 del / L858R: First line: osimertinib ± platinum-pemetrexed (FLAURA2) or amivantamab + lazertinib (MARIPOSA, OS benefit). Progression: re-biopsy/ctDNA; amivantamab + chemotherapy (MARIPOSA-2), Dato-DXd (TROPION-Lung05), platinum doublet; MET TKI add-on if MET-amplified; platinum-etoposide if small-cell transformation. ([Osimertinib](https://onco.cc/drugs/osimertinib/), [FLAURA2](https://onco.cc/trials/flaura2/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [MARIPOSA](https://onco.cc/trials/mariposa/), [Amivantamab + lazertinib (first-line EGFR NSCLC)](https://onco.cc/pairings/amivantamab-plus-lazertinib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [TROPION-Lung05](https://onco.cc/trials/tropion-lung05/), [EGFR exon 19 deletion & L858R](https://onco.cc/terms/egfr-exon19-l858r/), [EGFR C797S](https://onco.cc/terms/c797s/), [MET amplification (bypass resistance)](https://onco.cc/terms/met-amplification/), [Histologic transformation](https://onco.cc/terms/histologic-transformation/))
- Metastatic, EGFR exon 20 insertion: Amivantamab + platinum-pemetrexed (PAPILLON); sunvozertinib later line. ([Amivantamab](https://onco.cc/drugs/amivantamab/), [EGFR exon 20 insertion](https://onco.cc/terms/egfr-exon20-insertion/))
- Metastatic, ALK-rearranged: Lorlatinib (CROWN; 5-year PFS 60%) or alectinib first line; on progression, neladalkib (under review) or lorlatinib if not used; local therapy for oligoprogression; chemotherapy. ([Lorlatinib](https://onco.cc/drugs/lorlatinib/), [CROWN](https://onco.cc/trials/crown/), [Alectinib](https://onco.cc/drugs/alectinib/), [Neladalkib](https://onco.cc/drugs/neladalkib/), [ALKOVE-1](https://onco.cc/trials/alkove-1/), [Oligoprogression](https://onco.cc/terms/oligoprogression/))
- Metastatic, ROS1-rearranged: Repotrectinib or zidesamtinib (2026) first line; entrectinib/crizotinib alternatives. ([Repotrectinib](https://onco.cc/drugs/repotrectinib/), [Zidesamtinib](https://onco.cc/drugs/zidesamtinib/), [ROS1](https://onco.cc/targets/ros1/))
- Metastatic, KRAS G12C: First line: PD-(L)1 ± chemotherapy by PD-L1 (G12C inhibitor + IO combinations in phase 3: olomorasib SUNRAY-01, divarasib Krascendo 2). Second line: sotorasib or adagrasib (CodeBreaK 200, KRYSTAL-12); divarasib superior head-to-head (Krascendo 1, 2026). ([Sotorasib](https://onco.cc/drugs/sotorasib/), [Adagrasib](https://onco.cc/drugs/adagrasib/), [Divarasib](https://onco.cc/drugs/divarasib/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [CodeBreaK 200](https://onco.cc/trials/codebreak-200/), [KRYSTAL-12](https://onco.cc/trials/krystal-12/), [Krascendo 1](https://onco.cc/trials/krascendo-1/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/))
- Metastatic, BRAF V600E: Dabrafenib + trametinib or encorafenib + binimetinib first line; chemo-IO as alternative. ([Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [BRAF](https://onco.cc/targets/braf/))
- Metastatic, MET exon 14 skipping: Capmatinib or tepotinib first line; telisotuzumab vedotin for c-Met-overexpressing EGFR-wild-type disease after chemotherapy (accelerated 2025). ([Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [TeliMET NSCLC-01](https://onco.cc/trials/telimet-nsclc-01/), [MET](https://onco.cc/targets/met/))
- Metastatic, RET-fusion: Selpercatinib first line (LIBRETTO-431); pralsetinib alternative. ([Selpercatinib](https://onco.cc/drugs/selpercatinib/), [LIBRETTO-431](https://onco.cc/trials/libretto-431/), [Pralsetinib](https://onco.cc/drugs/pralsetinib/), [RET](https://onco.cc/targets/ret/))
- Metastatic, HER2-mutant: First line: zongertinib (2026) or chemo-IO; sevabertinib (Nov 2025) or T-DXd after prior therapy. ([Zongertinib](https://onco.cc/drugs/zongertinib/), [Sevabertinib](https://onco.cc/drugs/sevabertinib/), [SOHO-01](https://onco.cc/trials/soho-01/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [HER2](https://onco.cc/targets/her2/))
- Metastatic, NTRK-fusion: Larotrectinib, entrectinib, or repotrectinib (tumour-agnostic). ([Repotrectinib](https://onco.cc/drugs/repotrectinib/), [NTRK](https://onco.cc/targets/ntrk/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/))
- Metastatic, driver-negative, PD-L1 TPS ≥50%: Pembrolizumab (KEYNOTE-024) or cemiplimab monotherapy; add chemotherapy for high burden or rapid progression. Ivonescimab beat pembrolizumab in China (HARMONi-2); not approved in the US. ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [Tumour proportion score (TPS)](https://onco.cc/terms/tps/))
- Metastatic, driver-negative, PD-L1 TPS <50%: Pembrolizumab + platinum doublet (KEYNOTE-189 non-squamous; KEYNOTE-407 squamous); nivolumab + ipilimumab ± chemotherapy; tremelimumab + durvalumab + chemotherapy for PD-L1-negative or STK11/KEAP1-altered disease. Second line: docetaxel ± ramucirumab, TTFields, or trials of ADCs. ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [PD-1 blockade + chemotherapy in PD-L1-low NSCLC](https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/))
- Metastatic, squamous: Pembrolizumab + carboplatin + (nab-)paclitaxel (KEYNOTE-407); no ADC approved (TROPION-Lung01 showed no benefit in squamous); ivonescimab + chemotherapy under study (HARMONi-3). ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [TROPION-Lung01](https://onco.cc/trials/tropion-lung01/), [HARMONi-3](https://onco.cc/trials/harmoni-3/))

## State of the art

- 5-year PFS 60% with lorlatinib in ALK+ disease.
- Adjuvant osimertinib after surgery for EGFR-mutant disease roughly halves the risk of the cancer returning or of dying from it (ADAURA).
- First regimen to beat osimertinib (MARIPOSA) and first to beat pembrolizumab (ivonescimab, China).
- Lorlatinib: 5-year PFS 60% in ALK-positive disease, the longest for any targeted therapy in metastatic solid tumours.
- Adjuvant osimertinib after surgery roughly halves the risk of dying from EGFR-mutant disease (ADAURA, OS HR 0.49); adjuvant alectinib cuts recurrence by 76% (ALINA).
- Amivantamab + lazertinib is the first regimen to beat osimertinib, with median OS more than 12 months longer (MARIPOSA).
- Perioperative chemo-immunotherapy improves survival in resectable disease (CheckMate 816, KEYNOTE-671).
- Twelve targetable drivers each have an approved matched therapy; two oral HER2 TKIs (zongertinib, sevabertinib) arrived in 2025-26.
- First-in-class bispecific ivonescimab beat pembrolizumab on PFS and OS in China; the US decision (PDUFA 14 Nov 2026) hinges on HARMONi.
- 5-year survival with pembrolizumab in PD-L1-high disease is 31.9% in the KEYNOTE-024 five-year analysis, against 16.3% with platinum chemotherapy in the same trial.
- Two genomic landscapes, not one. Adenocarcinoma is oncogene-addicted: EGFR 12 to 47% by ancestry, KRAS 27 to 33%, ALK 3 to 6%, MET exon 14 skipping 2 to 4%, ERBB2 exon 20 insertion about 2%, ROS1 1 to 3%, RET 1 to 2%, BRAF V600E 1 to 2%, NTRK and NRG1 below 0.5%. Squamous carcinoma is copy-number driven: TP53 83 to 94%, SOX2 amplified about 40%, PIK3CA amplified 38%, TP63 about 30%, CDKN2A deleted 26%, FGFR1 17 to 22%, NFE2L2 12 to 15%, with targetable kinase alterations at 1 to 3%.
- Ancestry and smoking move the numbers more than anything else. EGFR is mutated in 47.4% of East Asian lung adenocarcinomas and 12.4% of the resected, mostly-smoker TCGA series; KRAS runs the other way, 29.7% against 10.9%; TP53 falls from 52 to 54% in smoker cohorts to 15.5% in never-smoker whole genomes.
- PD-L1 is the only measurement that changes first-line treatment, and it is not standardised: four scoring rules on five assays, with 22C3, 28-8 and SP263 agreeing on tumour cells, SP142 staining less and 73-10 more, and agreement between pathologists of 0.18 to 0.19 on immune cells against 0.86 to 0.93 on tumour cells.
- Tumour mutational burden failed as a selector. It tracks benefit from single-agent checkpoint blockade within every PD-L1 stratum, but the best data-derived cut-off was more than 19 mutations per megabase rather than the licensed 10, and it predicted nothing for pembrolizumab with chemotherapy, the regimen most patients receive.
- Resistance comes in three kinds with three different answers: a mutation in the target, a bypass receptor amplified, or a change of lineage into small-cell carcinoma. Which one it is cannot be guessed, so genotyping at progression is standard rather than optional.
- Small-cell lung cancer has one genotype and four states: TP53 and RB1 are both inactivated in nearly every tumour, and the classification that matters is transcriptional, ASCL1-dominant 69%, NEUROD1-dominant 17%, POU2F3 7%, and an inflamed class that gains most from immunotherapy.

## Open problems

- Screening uptake is under 20% in the US and lower elsewhere; never-smoker adenocarcinoma has no screening pathway.
- Resistance to every TKI is near-universal in metastatic disease; C797S has no approved fourth-generation EGFR inhibitor and small-cell transformation is undetectable by ctDNA.
- Squamous cell carcinoma has almost no targeted options and no approved ADC.
- KRAS G12C inhibitors add only ~1-2 months of PFS over docetaxel; non-G12C KRAS (G12D, G12V) remains undrugged outside trials.
- STK11/KEAP1 co-mutated and PD-L1-negative tumours respond poorly to immunotherapy.
- ADCs after TKI failure have not yet shown a survival benefit over platinum chemotherapy (HERTHENA-Lung02, TROPION-Lung01), and ILD limits combinations.
- Brain metastases occur in 30-50% of driver-positive patients; CNS activity now drives TKI choice, but leptomeningeal disease remains very hard to treat.
- Global access: most of the world's lung cancer patients never receive genomic profiling.
- The disease is still found late, and that is where most of the lost survival is. Fifty-one percent of American cases are already distant at diagnosis and survive 10.5 percent at five years, against 65.5 percent for the quarter found while the cancer is confined to the lung (SEER). Screening changes this only where it is offered, and it is offered to a minority of the people at risk even in the countries that have programmes.
- Screening cannot see never-smokers. Fifteen percent of UK cases and 15 to 25 percent worldwide arise in people who never smoked, and every eligibility rule starts from a smoking history, so the fastest-growing part of the disease is the part no programme is looking for.
- Never-smoker disease has no measured risk factor set to build a rule from. The largest UK prospective study found only three significant factors of 34 examined in 634,039 never-smoking women, and two of them, height and ethnicity, are not actionable (Million Women Study 2016).
- The staging change of January 2025 breaks every survival series that spans it. N2a and N2b patients were one group until 2024, several stage groups moved, and a cohort staged either side of the line cannot be pooled without restaging.
- NICE's diagnostic guideline is anchored two staging editions behind the clinic. NG122 states that its recommendations were developed with the 7th edition of the AJCC system while the ninth edition of TNM has been in force since January 2025, and the thresholds in the guideline (for example which stage triggers brain imaging) were fixed against the older groupings.
- More than half of KRAS-mutant lung adenocarcinoma has no approved inhibitor: G12C is 41 to 51% of KRAS records, and G12V, G12D, G12A, G13X and Q61X together are the rest.
- Squamous cell lung cancer still has no targeted therapy. Its three commonest alterations are a transcription factor amplicon (SOX2 and TP63), a tumour suppressor deletion (CDKN2A) and an antioxidant switch (NFE2L2 and KEAP1), and the one tractable-looking target, FGFR1 amplification, has not predicted response on its own.
- No biomarker selects patients for chemotherapy plus immunotherapy, the regimen most patients with driver-negative disease receive: tumour mutational burden, STK11, KEAP1 and KRAS status all failed to predict benefit from the combination in the randomised analyses.
- Fusion detection depends on assay design rather than on biology. A coding-exon panel returns wild-type for ALK, ROS1, RET, NTRK and NRG1 rearrangements and for MET exon 14 skipping, together about 8 to 10% of lung adenocarcinoma, and the patients most likely to be under-tested are never smokers, who are the likeliest to have one.
- The allelic phase of EGFR C797S with T790M decides whether a combination of inhibitors can work, and most reports do not state it.
- The transcriptional subtypes of small-cell lung cancer have no approved assay, no prospective trial, and a moving target: 37% of tumours express two of the four markers at once and platinum shifts tumours towards the inflamed state.
- PD-L1 thresholds are trial artefacts that cannot be transferred between assays, yet laboratories report a single percentage as though it were a property of the tumour.

## Notes

- What does non-small-cell lung cancer mean? It is not one tumour type but everything that is not small-cell lung cancer: adenocarcinoma, squamous cell carcinoma, large cell carcinoma and a handful of rarer types. The grouping exists because the first decision in treatment, whether surgery and driver-matched drugs are on the table at all, turns on that line. Together the three main types are about 85 percent of lung cancer.
- How is the type decided from a small biopsy? By morphology first, immunohistochemistry second and molecular tests last, which is the order the 2021 WHO classification sets out. On a poorly differentiated tumour a two-stain panel usually settles it: TTF-1 positive and p40 negative points to adenocarcinoma, p40 positive and TTF-1 negative to squamous cell carcinoma. It matters beyond the label, because adenocarcinoma is sequenced for drivers and squamous cell carcinoma usually is not, and because pemetrexed and bevacizumab are used in one and avoided in the other.
- What raises the risk, and how much of it can I change? In the UK, 79 percent of lung cancer cases are judged preventable. Tobacco accounts for 72 percent (71 percent active smoking, 1 percent second-hand smoke), workplace exposures 13 percent, outdoor air pollution 8 percent and ionising radiation including indoor radon 5 percent. Family history raises risk independently of smoking, by 82 percent if a sibling has had it and 25 to 37 percent if a parent has (Cancer Research UK).
- Is radon really a risk in Britain? Yes, as the largest single part of the 5 percent of cases caused by ionising radiation. An estimated 9 percent of European lung cancer deaths are linked to indoor radon, and risk rises about 16 percent for every 100 becquerels per cubic metre of the usual level in a home. Radon comes out of the ground, varies by geology rather than by anything a householder has done, can be measured with a posted detector and reduced by sealing and ventilation (Cancer Research UK).
- I have never smoked and I have been diagnosed. Why me? There is often no answer, and that is itself the finding. Fifteen percent of UK lung cancers are in never-smokers, and the largest British study of never-smoking women found only three significant factors out of 34 examined. Second-hand smoke explains an estimated 15 percent of never-smoker cases, radon and air pollution some more. What is known is that the tumour is far more likely to carry a targetable mutation, so the biopsy should be sequenced.
- Why did my GP send me for a chest X-ray rather than a scan? It is what NICE asks for. NG12 puts an urgent chest X-ray at the front of the pathway for people aged 40 and over with the symptom combinations it lists, and sends people straight to the suspected cancer pathway only when the X-ray already suggests cancer or when there is unexplained coughing of blood. A normal X-ray does not close the question: if symptoms persist, ask again.
- What is EBUS and why do I need it after a CT and a PET scan? Endobronchial ultrasound-guided transbronchial needle aspiration passes an ultrasound probe down the airway and puts a needle through the airway wall into the lymph nodes beside it. CT sees that a node is big and PET sees that it is active, but neither proves cancer, and a wrong nodal stage changes the whole plan. NICE asks for it, or for the oesophageal equivalent, or for both, whenever the nodal stage would change treatment, and keeps surgical staging for the cases where the needle comes back negative and the suspicion remains.
- Will I have a brain scan? It depends on the stage. NICE does not offer dedicated brain imaging for clinical stage 1 disease with no neurological symptoms, because the chance of finding a brain metastasis is about 4 percent and finding one rarely changes the lung operation. Stage 2 gets a contrast-enhanced brain CT and stage 3 a contrast-enhanced brain MRI, both before treatment with curative intent, because at those stages a metastasis is likelier and does change the plan.
- Why does my new report use different stage numbers from my old one? Because staging moved to the ninth edition of TNM on 1 January 2025. The T categories are the same, but N2 was split into N2a and N2b by how many mediastinal node stations are involved, M1c was split by how many organ systems carry metastases, and several combinations moved between stage groups: T1N1 is now IIA, T1N2a IIB, T3N2a IIIA, and T2aN2b and T2bN2b IIIB. Nothing about the tumour changed; the label did.
- Am I eligible for the NHS lung health check? In England the invitation goes to people aged 55 to 74 whose GP record shows they smoke or used to. A risk model, PLCOm2012 or the Liverpool Lung Project version 2, then decides who is scanned, at a PLCOm2012 threshold of 1.51 percent risk over six years; those above it are offered a low-dose CT scan every two years. The programme is arriving area by area and full coverage is expected in 2030, so an eligible person in an area not yet reached will not have been invited yet. Make sure the GP record says you smoke or used to, because the invitation is drawn from it.
- Is screening worth the radiation and the false alarms? On the balance the evidence supports, yes for people at high risk. Screening cuts lung cancer deaths by a fifth to a quarter and all-cause deaths by about 7 percent in the trial that measured it, at the cost of a false alarm rate that was 96.4 percent of positive scans in the American trial, 17 invasive procedures per 1,000 people screened, incidental findings in 4.4 to 40.7 percent, and an unresolved amount of overdiagnosis. The European protocol, which watches nodule volume and growth instead of diameter, referred only 2.1 percent of participants, so the harm figures differ by protocol as much as by population.
- What is the outlook? In the United States 29.5 percent of people are alive at five years, 65.5 percent for cancers still confined to the lung and 10.5 percent once the cancer has spread. In the UK 11.1 percent survive ten years or more, against 3.3 percent in the 1970s. These are averages over everybody diagnosed, including people whose disease was never treatable, and they lag the targeted drugs, immunotherapy and screening now in use by years.
- Living with non-small-cell lung cancer: This is orientation from public patient pages and guidelines, not advice for your case: your own team's instructions and 24-hour number come first. The decision pages, the appointment question sets and the first 60 days checklist are written once, on the parent lung cancer record, because most of them apply to both histologies; the red cards, the symptom and procedure records and the links above are attached here as well. Written from NICE NG122 and NG234 and the NHS, Roy Castle Lung Cancer Foundation, Macmillan, Cancer Research UK, Asthma + Lung UK, Maggie's and Marie Curie patient pages, all read on 25 September 2026.
- The science in detail, 1 of 8, in full; the one-sentence version is on the overview. The adenocarcinoma landscape. TP53 46 to 54%, KRAS 27 to 33% (G12C 41 to 51% of those records, about 13% of all adenocarcinomas), EGFR 12 to 47% by ancestry (exon 19 deletion 13 to 19%, L858R 9 to 21%, exon 20 insertion 1 to 3%, G719X, L861Q and S768I together 3 to 5%), KEAP1 11 to 18%, STK11 13 to 18%, CDKN2A deleted 15 to 20%, NKX2-1 amplified 8 to 14%, NF1 8 to 12%, SMARCA4 6 to 10%, RBM10 7 to 11%, PIK3CA 5 to 7%, ALK fusion 3 to 6%, MET exon 14 skipping 2 to 4% and MET amplification 2 to 3%, ERBB2 mutation 2 to 4% and amplification 1 to 3%, ROS1 fusion 1 to 3%, RET fusion 1 to 2%, BRAF V600E 1 to 2% against non-V600 3 to 4%, NRG1 fusion about 0.3% and NTRK fusion about 0.2%. Every figure names its cohort in the molecular table; the cBioPortal rows were computed on the TCGA PanCancer Atlas and 2014 deposits, the pan-lung TCGA and Broad set, two MSK-IMPACT cohorts (915 and 2,653 samples), the metastatic MSK cohort of 2,621, the Singaporean East Asian cohort, the never-smoker whole genomes and the CPTAC proteogenomic sets.
- The science in detail, 2 of 8, in full; the one-sentence version is on the overview. The squamous landscape, which shares an organ with the above and almost nothing else. TP53 83 to 94%; SOX2 amplified about 40% and TP63 about 30% on the 3q26 amplicon that also carries PIK3CA, amplified in 38% with mutation in 11 to 16%; CDKN2A deleted 26.3% with mutation in 15.1%, and CDKN2A with RB1 altered in 72% once methylation and exon skipping are counted; FGFR1 amplified 17 to 22%; NFE2L2 hotspot mutated 12 to 15% with KEAP1 10.1% and CUL3 4.5%, the pathway altered in 34%; PTEN lost in about 20%; KMT2D 22.9% and NOTCH1 7.9% as truncating tumour suppressor events. Against that, EGFR mutation is 2.9% and mostly non-canonical, KRAS 1.4%, and ALK, ROS1 and RET fusions are absent from the structural-variant profile. That is why guidelines recommend full molecular testing in squamous disease only for never smokers, small biopsies and mixed histology.
- The science in detail, 3 of 8, in full; the one-sentence version is on the overview. Small-cell disease. Biallelic TP53 and RB1 inactivation in nearly all of 110 sequenced genomes, sometimes by complex rearrangement, so mutation calls read lower (85.8% and 72.5%) than the biology; the two RB1 wild-type cases reached the same end by chromothripsis and cyclin D1 overexpression. NOTCH family inactivation in 25%, oncogenic TP73 rearrangements, and chromatin regulators (KMT2D 18.3%, EP300 10.8%, CREBBP 9.2%, KMT2C 10.0%) make up the rest, with kinase mutations only in rare individual cases. The clinically useful classification is transcriptional rather than genomic: 69% ASCL1-dominant, 17% NEUROD1-dominant, 7% POU2F3-positive and the remainder double-negative, with 37% co-expressing ASCL1 and NEUROD1. The fourth class is defined by an inflamed signature and gains most from adding immunotherapy to chemotherapy; the others carry vulnerabilities to PARP, Aurora kinase and BCL-2 inhibition, and DLL3 expression follows the neuroendocrine-high subtypes rather than the whole disease.
- The science in detail, 4 of 8, in full; the one-sentence version is on the overview. PD-L1, the one protein biomarker that changes treatment. Four scoring rules on five assays: the tumour proportion score (22C3, tumour cells only, at least 100 counted), the tumour-cell score (28-8, SP263, SP142), the immune-cell area score (SP142) and the combined positive score used outside the lung. The thresholds are trial artefacts: 50% or more by 22C3 for first-line pembrolizumab monotherapy, where progression-free survival was 10.3 against 6.0 months; 1% or more after platinum; the SP142 combination of tumour cells 50% or more or immune cells 10% or more for first-line atezolizumab, where overall survival was 20.2 against 13.1 months; and 5% or more by 28-8, at which first-line nivolumab failed outright. Analytically, 22C3, 28-8 and SP263 are interchangeable on tumour cells, SP142 stains fewer tumour cells (mean score 1.99 against 2.96) and 73-10 more, agreement between pathologists is 0.86 to 0.93 on tumour cells and 0.18 to 0.19 on immune cells, cytology cell blocks score reliably (0.78 to 0.85) and digital images agree with glass slides above 0.96.
- The science in detail, 5 of 8, in full; the one-sentence version is on the overview. Tumour mutational burden and why it failed. It is a real biological correlate: whole-exome sequencing first tied non-synonymous burden to pembrolizumab response in lung cancer, panel-based estimates track exome estimates at rho 0.86, burden and PD-L1 are independent, and across 1,552 patients burden tracked response, progression-free survival and overall survival within every PD-L1 stratum, with response ranging from 57% where both were high to 8.7% where neither was. It failed as a selector for three reasons. The unit is not standardised (per megabase on a panel, per exome on sequencing, a plasma score), the best data-derived threshold in the largest cohort was more than 19 per megabase rather than the licensed 10, and the effect is confined to single-agent immunotherapy: in KEYNOTE-189 and KEYNOTE-407 continuous burden showed no association with survival for pembrolizumab plus chemotherapy in either histology, and neither did STK11, KEAP1 or KRAS status. CheckMate 227 reported a progression-free survival benefit in the high-burden group and then found its survival benefit did not depend on burden at all.
- The science in detail, 6 of 8, in full; the one-sentence version is on the overview. The never-smoker disease. Whole genomes of 232 never-smoker lung cancers carry no strong tobacco signature even with recorded secondhand exposure, and split into three copy-number subtypes: piano, the dominant and slow one, with somatic UBA1 mutations, germline androgen receptor variants, low mutation burden, high intratumour heterogeneity, long telomeres, frequent KRAS and driver progenitor cells dating back many years; mezzo-forte, with specific amplifications and EGFR mutations; and forte, with whole-genome doubling. The driver spectrum in the same cohort is EGFR 28.4%, ALK fusion 5.6%, ERBB2 exon 20 insertion 3.4%, MET exon 14 2.2%, ROS1 2.2%, RET 1.3% and NRG1 0.9%, with KRAS at only 7.3% and led by G12D, and TP53 at 15.5%, STK11 at 2.2% and KEAP1 at 0.4%. Ancestry is a separate axis: East Asian adenocarcinomas have more stable genomes with fewer mutations and fewer copy-number changes, a difference that is larger in smokers, and EGFR at 47.4%.
- The science in detail, 7 of 8, in full; the one-sentence version is on the overview. Resistance, in three categories. On-target mutation: EGFR T790M in 63% of rebiopsies after a first-generation inhibitor, then C797S in 22% of osimertinib resistance, where the allelic phase with T790M decides whether a first-plus-third-generation combination can cover it; in ALK-rearranged disease, a diverse spectrum after crizotinib and G1202R after second-generation inhibitors, with lorlatinib response 69% where an ALK mutation is present and 27% where it is not. Bypass activation: MET amplification in 5 to 22% and HER2 amplification in 13%, both answered by adding an inhibitor rather than swapping one. Lineage change: small-cell transformation in 3 to 14%, requiring RB1 and TP53 loss, predictable from the baseline genotype with a 43-fold risk, treated as small-cell disease with platinum and etoposide and unresponsive to checkpoint blockade. Losing T790M at osimertinib resistance, which happens in 68% of cases, signals a pre-existing competing clone and a much shorter time on treatment (6.1 against 15.2 months).
- The science in detail, 8 of 8, in full; the one-sentence version is on the overview. Testing, in practice. Plasma and tissue together at diagnosis: cell-free DNA found a guideline biomarker in 27.3% of 282 patients against 21.3% by tissue, with 100% positive predictive value for the alterations that have approved drugs and a median turnaround of 9 against 15 days, and using both raised detection by 48%. A negative plasma result rules nothing out, since clinical sensitivity against tissue is 80% and the misses concentrate in low-volume, intrathoracic and brain-confined disease. What tissue alone can miss is different: fusions and MET exon 14 skipping need intron baiting or RNA, PD-L1 cannot be read from plasma at all, and histology has no liquid substitute. The practical rule is tissue stewardship, cutting unstained slides at diagnosis and avoiding reflex stains that consume the block, with cytology cell blocks used where they are the only material. The guideline requires ROS1 for every adenocarcinoma, 5% sensitivity for EGFR T790M in acquired resistance, immunohistochemistry as a screen for ALK and ROS1 but not for EGFR, and plasma to rule in rather than out.
- Frequencies marked cBioPortal were computed from the public API on 25 September 2026 on the sequenced sample lists of luad_tcga_pan_can_atlas_2018 (566), lusc_tcga_pan_can_atlas_2018 (484 sequenced, 487 with copy number), luad_tcga_pub (230), lusc_tcga_pub (178), nsclc_tcga_broad_2016 (1,144), lung_msk_2017 (915), nsclc_ctdx_msk_2022 (2,621), luad_mskcc_2023_met_organotropism (2,653 sequenced, 2,422 with copy number and structural variants), luad_oncosg_2020 (302), lung_nci_2022 (232), sclc_ucologne_2015 (120), nsclc_pd1_msk_2018 (240), luad_cptac_2020 (110) and lusc_cptac_2021 (108), as sample-level counts of non-synonymous mutation, high-level amplification, deep deletion or structural variant. They are not the papers' own percentages, which are quoted alongside.
- What the panels cannot see. Fusion counts here come from the structural-variant profile, which requires intron baiting or RNA, so every fusion rate is a floor: ALK reads 3 to 6% on panels against 8% by fluorescence in situ hybridisation in the Lung Cancer Mutation Consortium, and NRG1 reads 0.3% by RNA sequencing against near zero on most DNA panels. Point mutations in ALK, ROS1, RET and NTRK read 2 to 8% in exome cohorts and are almost all passengers in a tobacco-mutated genome. The Cologne small-cell deposit carries no copy-number profile, so MYC family amplification rates cannot be recomputed from it, and biallelic TP53 and RB1 inactivation by complex rearrangement is invisible to a mutation call, which is why the deposit reads 85.8% and 72.5% where the paper reports near-universal loss. The TRACERx cohort is multiregion, so its sample counts are regions rather than patients and no frequency is taken from it here.
- EGFR class counts are sample-level and a tumour with both an exon 19 deletion and T790M is counted in both classes, which is deliberate: the point of reading the classes separately is that a treated patient carries both. KRAS, BRAF and NFE2L2 allele shares are counts of mutation records over all records for that gene in a study, so a tumour with two mutations in one gene counts twice. T790M and C797S rates in the MSK cohorts are inflated relative to the untreated population because those cohorts are largely treated patients resequenced at progression.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer
- GLOBOCAN trachea, bronchus and lung fact sheet (IARC Global Cancer Observatory, 2024 estimates): https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf
- SEER Cancer Stat Facts: lung and bronchus cancer (rates, stage distribution, survival by stage, age and race): https://seer.cancer.gov/statfacts/html/lungb.html
- CRUK: lung cancer statistics (incidence, mortality, survival, early diagnosis, treatment): https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer
- CRUK: lung cancer incidence statistics: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence
- CRUK: lung cancer mortality statistics (including mortality by deprivation): https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality
- CRUK: lung cancer survival statistics (by age, deprivation and over time): https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/survival
- CRUK: lung cancer risk factors (attributable fractions for the UK): https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/risk-factors
- NHS: lung cancer: https://www.nhs.uk/conditions/lung-cancer/
- NHS: symptoms of lung cancer (when to see a GP, when to call 111 and when to call 999): https://www.nhs.uk/conditions/lung-cancer/symptoms/
- NHS: lung cancer screening (who is invited to a lung health check and what happens): https://www.nhs.uk/tests-and-treatments/lung-cancer-screening/
- NICE NG12: suspected cancer, recommendations by site (lung and pleural cancers 1.1.1 to 1.1.6): https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer
- NICE NG122: lung cancer, diagnosis and staging (published 28 March 2019, last updated 8 March 2024): https://www.nice.org.uk/guidance/ng122/chapter/Diagnosis-and-staging
- NICE NG209: tobacco, preventing uptake, promoting quitting and treating dependence (published 30 November 2021, last updated 4 February 2025): https://www.nice.org.uk/guidance/ng209
- UK National Screening Committee: lung cancer screening recommendation (June 2022 review): https://view-health-screening-recommendations.service.gov.uk/lung-cancer/
- GOV.UK: new lung cancer screening roll out to detect cancer sooner (26 June 2023): https://www.gov.uk/government/news/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner
- National Lung Screening Trial Research Team, N Engl J Med 2011: reduced lung-cancer mortality with low-dose computed tomographic screening (53,454 people): https://doi.org/10.1056/nejmoa1102873
- de Koning, N Engl J Med 2020: NELSON, reduced lung-cancer mortality with volume CT screening in a randomised trial (13,195 men and 2,594 women): https://doi.org/10.1056/nejmoa1911793
- US Preventive Services Task Force, JAMA 2021: screening for lung cancer, recommendation statement (annual low-dose CT at 50 to 80 with 20 pack-years, grade B): https://doi.org/10.1001/jama.2021.1117
- Jonas, JAMA 2021: screening for lung cancer with low-dose computed tomography, updated evidence report for the US Preventive Services Task Force (223 publications, 7 randomised trials, 86,486 people): https://doi.org/10.1001/jama.2021.0377
- Nature Medicine 2026: implementation of the NHS England Lung Cancer Screening Programme over 5 years (over two million invited, 7,193 cancers to March 2025): https://doi.org/10.1038/s41591-026-04292-y
- Br J Hosp Med 2026: how to translate quality standards into good lung cancer screening programmes, the UK experience: https://doi.org/10.31083/bjhm53142
- Br J Cancer 2021: comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom (273,789 people in three cohorts): https://doi.org/10.1038/s41416-021-01278-0
- Cancer Epidemiol 2023: the value of blood-based measures of liver function and urate in lung cancer risk prediction (388,199 UK Biobank participants; the 1.51 percent six-year threshold): https://doi.org/10.1016/j.canep.2023.102354
- Br J Radiol 2025: something old something new, introduction to the ninth edition TNM classification of lung cancer (effective 1 January 2025): https://doi.org/10.1093/bjr/tqaf161
- Rami-Porta, J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for revision of the TNM stage groups in the forthcoming ninth edition (76,518 patients analysed of 124,581 registered): https://doi.org/10.1016/j.jtho.2024.02.011
- J Thorac Oncol 2024: IASLC lung cancer staging project, proposals for the revisions of the T descriptors in the forthcoming ninth edition (no change recommended): https://doi.org/10.1016/j.jtho.2023.12.006
- J Thorac Oncol 2024: IASLC staging project for lung cancer, proposals for the revision of the M descriptors in the forthcoming ninth edition (M1c split into M1c1 and M1c2): https://doi.org/10.1016/j.jtho.2024.01.019
- J Thorac Oncol 2023: IASLC lung cancer staging project, the new database to inform revisions in the ninth edition of the TNM classification: https://doi.org/10.1016/j.jtho.2023.01.088
- Int J Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change: https://doi.org/10.1002/ijc.70561
- Nicholson, J Thorac Oncol 2022: the 2021 WHO classification of lung tumours, impact of advances since 2015: https://doi.org/10.1016/j.jtho.2021.11.003
- Lancet Respir Med 2025: estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time (GLOBOCAN 2022 with Cancer Incidence in Five Continents): https://doi.org/10.1016/s2213-2600(24)00428-4
- BJC Reports 2023: lung cancer in never smokers, development of a UK national research strategy (127 surveys, 190 attendees): https://doi.org/10.1038/s44276-023-00006-w
- BMJ Open Respir Res 2026: observational study of predictors and outcomes of lung cancer in never-smokers in the UK (OLIVE), study protocol: https://doi.org/10.1136/bmjresp-2025-003966
- Pirie, Int J Cancer 2016: lung cancer in never smokers in the UK Million Women Study (634,039 never smokers, 1,469 lung cancers over 14 years): https://doi.org/10.1002/ijc.30084
- Health Sci Rep 2026: lung cancer in never smokers, an underappreciated public health burden: https://doi.org/10.1002/hsr2.73080
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
- Ding et al., BMJ Open 2024: applying the ESMO Magnitude of Clinical Benefit Scale to antibody-drug conjugates in solid cancers, a systematic analysis of phase 3 and pivotal phase 2 trials: https://pmc.ncbi.nlm.nih.gov/articles/PMC11163648/
- NHS: treatment for lung cancer: https://www.nhs.uk/conditions/lung-cancer/treatment/
- NICE NG122: lung cancer, palliative interventions and supportive and palliative care: https://www.nice.org.uk/guidance/ng122/chapter/Palliative-interventions-and-supportive-and-palliative-care
- NICE NG122: lung cancer, support from clinical nurse specialists: https://www.nice.org.uk/guidance/ng122/chapter/Support-from-clinical-nurse-specialists
- NICE NG122: lung cancer, follow-up and patient perspectives: https://www.nice.org.uk/guidance/ng122/chapter/Follow-up-and-patient-perspectives
- Roy Castle Lung Cancer Foundation: living with lung cancer: https://roycastle.org/learn-about-lung-cancer/living-with-cancer/
- Roy Castle Lung Cancer Foundation: the support available to you: https://roycastle.org/our-support/
- Macmillan: non-small cell lung cancer (NSCLC): https://www.macmillan.org.uk/cancer-information-and-support/lung-cancer/non-small-cell-lung-cancer
- Macmillan: breathlessness: https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/breathlessness
- Macmillan: superior vena cava obstruction (SVCO): https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/superior-vena-cava-obstruction
- Cancer Research UK: living with lung cancer: https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with
- Cancer Research UK: coping with breathlessness when you have lung cancer: https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping-with-breathlessness
- Cancer Research UK: coping and support when you have lung cancer: https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping
- Cancer Research UK: fluid on the lungs (pleural effusion): https://www.cancerresearchuk.org/about-cancer/coping/physically/breathing-problems/fluid-on-lungs-pleural-effusion
- Asthma + Lung UK: breathlessness: https://www.asthmaandlung.org.uk/symptoms-tests-treatments/symptoms/breathlessness
- Maggie's: support and information: https://www.maggies.org/support-and-information/
- Marie Curie: what is palliative care?: https://www.mariecurie.org.uk/information/getting-care/palliative-care
- Temel et al., early palliative care for patients with metastatic non-small-cell lung cancer (NEJM 2010): https://doi.org/10.1056/NEJMoa1000678
- National Lung Cancer Audit: State of the Nation 2026: https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-State-of-the-Nation-Report-2026.pdf
- NHS England: National Optimal Lung Cancer Pathway v4.0: https://rmpartners.nhs.uk/wp-content/uploads/2024/09/national-optimal-lung-cancer-pathway_v4_01jan2024.pdf
- Roy Castle Lung Cancer Foundation: https://roycastle.org/

## Connected records

- cancers: [Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/), [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Adenosquamous carcinoma of the lung](https://onco.cc/cancers/lung-adenosquamous-carcinoma/), [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [Basaloid squamous cell carcinoma of the lung](https://onco.cc/cancers/basaloid-squamous-cell-carcinoma-lung/), [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/), [Brain metastases (secondary brain tumours)](https://onco.cc/cancers/secondary-brain-tumours/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Invasive mucinous adenocarcinoma of the lung](https://onco.cc/cancers/invasive-mucinous-adenocarcinoma-lung/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Large cell carcinoma of the lung](https://onco.cc/cancers/large-cell-lung-carcinoma/), [Large cell neuroendocrine carcinoma of the lung](https://onco.cc/cancers/lung-lcnec/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Lymphoepithelial carcinoma of the lung](https://onco.cc/cancers/lymphoepithelial-carcinoma-lung/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [NTRK fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ntrk-fusion-nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Pulmonary blastoma (adult)](https://onco.cc/cancers/pulmonary-blastoma/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [RET fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ret-fusion-nsclc/), [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/), [Sarcomatoid carcinoma of the lung](https://onco.cc/cancers/pulmonary-sarcomatoid-carcinoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- roadmaps: [ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs](https://onco.cc/roadmaps/adc-generations/), [Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity](https://onco.cc/roadmaps/immunotherapy-roadmap/), [KRAS roadmap: undruggable → G12C → pan-RAS](https://onco.cc/roadmaps/kras-roadmap/), [Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch](https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/), [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/)
- pairings: [ADC + checkpoint inhibitor](https://onco.cc/pairings/adc-plus-io/), [Amivantamab + lazertinib (first-line EGFR NSCLC)](https://onco.cc/pairings/amivantamab-plus-lazertinib/), [BRAF inhibitor + MEK inhibitor](https://onco.cc/pairings/braf-plus-mek/), [Caution: proton therapy vs IMRT](https://onco.cc/pairings/proton-vs-imrt/), [Caution: TIGIT + PD-(L)1 blockade](https://onco.cc/pairings/tigit-plus-pd1-caution/), [EGFR TKI → ADC on progression](https://onco.cc/pairings/tki-then-adc-lung/), [PD-1 blockade + chemotherapy in PD-L1-low NSCLC](https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/), [PD-1 blockade + VEGF inhibition](https://onco.cc/pairings/io-plus-vegf/), [Radiotherapy + immunotherapy](https://onco.cc/pairings/radiation-plus-io/), [Sequence: targeted therapy before immunotherapy in driver-positive NSCLC](https://onco.cc/pairings/targeted-before-io-nsclc/), [TROP2 PET → TROP2 ADC selection](https://onco.cc/pairings/trop2-pet-to-adc/)
- biomarkers: [ALK fusion (ALK-positive)](https://onco.cc/biomarkers/alk-fusion/), [ALK kinase-domain resistance mutation (G1202R and the rest)](https://onco.cc/biomarkers/alk-resistance-mutation/), [BRAF class II and class III mutations (non-V600)](https://onco.cc/biomarkers/braf-class-ii-iii/), [BRAF V600E (and V600K)](https://onco.cc/biomarkers/braf-v600e/), [c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)](https://onco.cc/biomarkers/met-overexpression/), [CEACAM5 expression](https://onco.cc/biomarkers/ceacam5-expression/), [ctDNA MRD positivity (molecular residual disease after curative treatment)](https://onco.cc/biomarkers/ctdna-mrd-positive/), [EGFR C797S (and its phase with T790M)](https://onco.cc/biomarkers/egfr-c797s/), [EGFR exon 19 deletion](https://onco.cc/biomarkers/egfr-exon-19-deletion/), [EGFR exon 20 insertion](https://onco.cc/biomarkers/egfr-exon-20-insertion/), [EGFR L858R](https://onco.cc/biomarkers/egfr-l858r/), [EGFR T790M](https://onco.cc/biomarkers/egfr-t790m/), [HER2 (ERBB2) activating mutation](https://onco.cc/biomarkers/her2-mutation/), [HER3 expression](https://onco.cc/biomarkers/her3-expression/), [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/), [KRAS G12D (and other non-G12C KRAS mutations)](https://onco.cc/biomarkers/kras-g12d/), [MET amplification (gene copy number)](https://onco.cc/biomarkers/met-amplification-readout/), [MET exon 14 skipping mutation](https://onco.cc/biomarkers/met-ex14/), [NRG1 gene fusion](https://onco.cc/biomarkers/nrg1-fusion/), [NTRK1/2/3 gene fusion](https://onco.cc/biomarkers/ntrk-fusion/), [PD-L1 IC score (immune-cell score, SP142)](https://onco.cc/biomarkers/pd-l1-ic-score/), [PD-L1 TC score (tumour-cell score, SP263 and 28-8)](https://onco.cc/biomarkers/pd-l1-tc-score/), [PD-L1 TPS (tumour proportion score)](https://onco.cc/biomarkers/pd-l1-tps/), [PIK3CA mutation](https://onco.cc/biomarkers/pik3ca-hotspot-mutation/), [RET fusion and RET mutation](https://onco.cc/biomarkers/ret-fusion/), [ROS1 fusion (ROS1-positive)](https://onco.cc/biomarkers/ros1-fusion/), [STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma](https://onco.cc/biomarkers/stk11-keap1-loss/), [TMB-high (tumour mutational burden >= 10 mutations per megabase)](https://onco.cc/biomarkers/tmb-high/), [TROP2 expression](https://onco.cc/biomarkers/trop2-expression/)
- technologies: [After treatment in Germany: a rehabilitation entitlement, not a leaflet](https://onco.cc/technologies/rejuv-access-survivorship-care-germany/), [After treatment in the UK: personalised care, and follow-up you lead yourself](https://onco.cc/technologies/rejuv-access-survivorship-care-uk/), [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [AI scoring of biomarkers and grade on pathology slides](https://onco.cc/technologies/ai-pathology-scoring/), [Alternative medicine used instead of standard treatment](https://onco.cc/technologies/alternative-medicine-instead-of-treatment/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Asking people how they are, every week, as a treatment in its own right](https://onco.cc/technologies/rejuv-measure-epro-as-treatment/), [ATR and CHK1 inhibitors](https://onco.cc/technologies/atr-chk1-inhibitors/), [Biology-guided radiotherapy (RefleXion X1, SCINTIX)](https://onco.cc/technologies/biology-guided-radiotherapy/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Bone-modifying agents (bisphosphonates, denosumab)](https://onco.cc/technologies/bone-modifying-agents/), [Breath and volatile-organic-compound detection](https://onco.cc/technologies/breath-vocs/), [Breathing and exercise capacity after lung resection](https://onco.cc/technologies/rejuv-rehab-respiratory/), [C-arm medical linear accelerators (TrueBeam, Versa HD and others)](https://onco.cc/technologies/c-arm-linac/), [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/), [Cancer pain management](https://onco.cc/technologies/pain-management/), [Cancer rehabilitation: the discipline that puts function back](https://onco.cc/technologies/rejuv-rehab-cancer-rehabilitation/), [Cancer-associated thrombosis prevention and treatment](https://onco.cc/technologies/cancer-associated-thrombosis/), [Cardiopulmonary exercise testing: the hardest number in recovery](https://onco.cc/technologies/rejuv-measure-cardiopulmonary-exercise-testing/), [cfDNA fragmentomics](https://onco.cc/technologies/fragmentomics/), [Clonal evolution and branching models](https://onco.cc/technologies/clonal-evolution-models/), [Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)](https://onco.cc/technologies/closed-system-transfer-devices/), [Cognitive behavioural therapy for fatigue and distress](https://onco.cc/technologies/cbt-fatigue-distress/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Cryoablation systems](https://onco.cc/technologies/cryoablation-systems/), [CT (computed tomography)](https://onco.cc/technologies/ct/), [CT body composition and sarcopenia measurement](https://onco.cc/technologies/ct-body-composition-sarcopenia/), [CyberKnife robotic radiosurgery](https://onco.cc/technologies/cyberknife/), [Cytogenetics and FISH](https://onco.cc/technologies/cytogenetics-fish/), [Depression during and after cancer: the interview-based prevalence, and the care model that works](https://onco.cc/technologies/rejuv-mind-depression-after-cancer/), [Dietary fibre and the gut microbiome for immunotherapy response](https://onco.cc/technologies/dietary-fibre-microbiome-io/), [Dietary supplements during cancer treatment: interactions and harms](https://onco.cc/technologies/dietary-supplements-treatment-interactions/), [Early integrated palliative care](https://onco.cc/technologies/palliative-care/), [Employment rights with cancer in the United Kingdom](https://onco.cc/technologies/rejuv-life-employment-rights-uk/), [Employment rights with cancer in the United States](https://onco.cc/technologies/rejuv-life-employment-rights-us/), [Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/), [EORTC QLQ-C30: the questionnaire most cancer trials use](https://onco.cc/technologies/rejuv-measure-eortc-qlq-c30/), [EQ-5D: health reduced to one number, and what that number is for](https://onco.cc/technologies/rejuv-measure-eq-5d/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [FACT-G and the FACIT family: the other main questionnaire](https://onco.cc/technologies/rejuv-measure-fact-and-facit/), [Faecal microbiota transplantation for PD-1 non-responders](https://onco.cc/technologies/fmt-checkpoint-nonresponders/), [Fatigue after cancer treatment: what actually works](https://onco.cc/technologies/cancer-related-fatigue-management/), [Financial toxicity and financial navigation](https://onco.cc/technologies/financial-navigation/), [Fish oil (EPA) for cancer weight loss](https://onco.cc/technologies/omega3-epa-cachexia/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Genetically engineered mouse models](https://onco.cc/technologies/genetically-engineered-mouse-models/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Getting psychological help after cancer: the stepped-care model, and what is actually commissioned](https://onco.cc/technologies/rejuv-mind-access-to-psychological-care/), [Going back to driving, lifting and exercise](https://onco.cc/technologies/rejuv-rehab-driving-and-exercise-return/), [Hearing and tinnitus after platinum chemotherapy](https://onco.cc/technologies/hearing-after-platinum-chemotherapy/), [Histopathology & immunohistochemistry](https://onco.cc/technologies/histopathology-ihc/), [How recovery is measured: the questionnaires behind the numbers](https://onco.cc/technologies/rejuv-measure-patient-reported-outcomes/), [Hydrazine sulfate](https://onco.cc/technologies/hydrazine-sulfate/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/), [Immuno-PET](https://onco.cc/technologies/immuno-pet/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)](https://onco.cc/technologies/in-room-imaging-systems/), [Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)](https://onco.cc/technologies/intraoperative-fluorescence-imaging-systems/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Low-dose CT lung screening](https://onco.cc/technologies/low-dose-ct-screening/), [Measuring fear of recurrence: the FCRI and its cut-off](https://onco.cc/technologies/rejuv-measure-fear-of-recurrence-inventory/), [Measuring muscle and fat on scans the patient already had](https://onco.cc/technologies/rejuv-measure-body-composition/), [Microwave and radiofrequency ablation systems](https://onco.cc/technologies/microwave-rf-ablation/), [Money after treatment: what the cost of cancer does once the treatment has finished](https://onco.cc/technologies/rejuv-life-money-after-treatment/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [mRNA and lipid nanoparticle manufacturing](https://onco.cc/technologies/mrna-lnp-manufacturing/), [Multidisciplinary tumour boards](https://onco.cc/technologies/multidisciplinary-tumour-board/), [Muscle and strength after treatment: sarcopenia, cachexia and what rebuilds](https://onco.cc/technologies/muscle-recovery-after-cancer-treatment/), [MUSK (Stanford, vision-language pathology)](https://onco.cc/technologies/musk/), [Nerve damage from chemotherapy: what recovers, and what helps](https://onco.cc/technologies/cipn-recovery-and-treatment/), [NHS Targeted Lung Health Check (lung cancer screening programme)](https://onco.cc/technologies/nhs-targeted-lung-health-check/), [Nutrition support and cachexia management](https://onco.cc/technologies/oncology-nutrition/), [Oncology information and record-and-verify systems (ARIA, MOSAIQ)](https://onco.cc/technologies/oncology-information-systems/), [Oncology nutrition assessment and medical nutrition therapy](https://onco.cc/technologies/nutrition-screening-mnt/), [Palliative radiotherapy](https://onco.cc/technologies/palliative-radiotherapy/), [Parsortix label-free circulating tumour cell harvest](https://onco.cc/technologies/parsortix-ctc-harvest/), [Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)](https://onco.cc/technologies/patient-positioning-surface-guidance-systems/), [Peer support and support groups](https://onco.cc/technologies/peer-support-groups/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/), [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [PET/CT](https://onco.cc/technologies/pet-ct/), [Photon-counting CT](https://onco.cc/technologies/photon-counting-ct/), [Platinum agents](https://onco.cc/technologies/platinum/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [PRO-CTCAE: side effects graded by the person having them](https://onco.cc/technologies/rejuv-measure-pro-ctcae/), [Probiotics, antibiotics and stewardship around immunotherapy](https://onco.cc/technologies/probiotics-antibiotic-stewardship-io/), [PROMIS: the item banks that let a short questionnaire be precise](https://onco.cc/technologies/rejuv-measure-promis/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Psycho-oncology and distress screening](https://onco.cc/technologies/psycho-oncology/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://onco.cc/technologies/quantitative-imaging-biomarkers/), [Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)](https://onco.cc/technologies/radiotherapy-qa-phantoms-dosimeters/), [Residual disease kinetics (BCR-ABL halving and ctDNA slopes)](https://onco.cc/technologies/mrd-kinetics-models/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/), [Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)](https://onco.cc/technologies/respiratory-gating-tumour-tracking-systems/), [Respiratory motion management (4D-CT, gating, breath-hold, tracking)](https://onco.cc/technologies/respiratory-motion-management/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [Robotic and navigational bronchoscopy](https://onco.cc/technologies/robotic-bronchoscopy/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Screening for distress: what the thermometer can and cannot do](https://onco.cc/technologies/rejuv-mind-distress-screening/), [Shark cartilage (AE-941, Neovastat)](https://onco.cc/technologies/shark-cartilage/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/), [Sleeping tablets after cancer: what they do and what they do not](https://onco.cc/technologies/rejuv-mind-sleeping-tablets-after-cancer/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Smoking cessation in cancer patients](https://onco.cc/technologies/smoking-cessation-after-diagnosis/), [Stereotactic ablative radiotherapy for oligometastatic disease](https://onco.cc/technologies/sabr-oligometastases/), [Surgical robots: da Vinci, Hugo, Versius and single-port systems](https://onco.cc/technologies/surgical-robot-platforms/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Sybil (MIT/MGH lung cancer risk from CT)](https://onco.cc/technologies/sybil/), [The carer's own recovery: what is known about the person who is not the patient](https://onco.cc/technologies/rejuv-life-carers/), [The exercise prescription after cancer: the dose the guidelines state](https://onco.cc/technologies/exercise-prescription-after-cancer/), [The four Rs and accelerated repopulation](https://onco.cc/technologies/fractionation-repopulation-models/), [The gap between the rehabilitation people need and the rehabilitation they are offered](https://onco.cc/technologies/rejuv-rehab-provision-gap/), [The questionnaires that were never returned, and the people never asked](https://onco.cc/technologies/rejuv-measure-missing-data-and-who-is-not-asked/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/), [TIL therapy](https://onco.cc/technologies/til-therapy/), [TIM-3 blockade](https://onco.cc/technologies/tim3-blockade/), [TROP2 PET](https://onco.cc/technologies/trop2-pet/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [Tumour clonal evolution tracking](https://onco.cc/technologies/clonal-evolution-tracking/), [Tumour mutational burden testing](https://onco.cc/technologies/tmb-testing/), [Tumour treating fields (TTFields)](https://onco.cc/technologies/ttfields/), [Tumour volume doubling time](https://onco.cc/technologies/tumour-doubling-time/), [Walking, gripping and standing up: the tests that take five minutes](https://onco.cc/technologies/rejuv-measure-functional-tests/), [Wearables and step counts: measuring what someone actually does](https://onco.cc/technologies/rejuv-measure-wearables-and-step-counts/), [What a difference has to be before a person would notice it](https://onco.cc/technologies/rejuv-measure-minimally-important-difference/), [What a prehabilitation programme actually contains, and how long it needs](https://onco.cc/technologies/rejuv-rehab-prehabilitation-programme/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/), [What has actually been implemented since those trials, and what has not](https://onco.cc/technologies/rejuv-measure-epro-implementation/), [What recovery costs in the United States](https://onco.cc/technologies/rejuv-access-what-it-costs-us/), [What the randomised trials of prehabilitation found, operation by operation](https://onco.cc/technologies/rejuv-rehab-prehabilitation-evidence/), [Where rehabilitation is commissioned, and who misses out](https://onco.cc/technologies/rejuv-rehab-commissioning-inequity/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- targets: [ABCB1](https://onco.cc/targets/abcb1/), [ABCC10](https://onco.cc/targets/abcc10/), [ABL2](https://onco.cc/targets/abl2/), [ACTA1](https://onco.cc/targets/acta1/), [ACTL6A](https://onco.cc/targets/actl6a/), [ACVR1B](https://onco.cc/targets/acvr1b/), [Adenosine A2A receptor (ADORA2A)](https://onco.cc/targets/adora2a/), [AFF3](https://onco.cc/targets/aff3/), [ALK](https://onco.cc/targets/alk/), [ANK1](https://onco.cc/targets/ank1/), [ARAF](https://onco.cc/targets/araf/), [AREG](https://onco.cc/targets/areg/), [ARHGEF10](https://onco.cc/targets/arhgef10/), [ATF7IP](https://onco.cc/targets/atf7ip/), [ATR](https://onco.cc/targets/atr/), [AURKA](https://onco.cc/targets/aurka/), [BARD1](https://onco.cc/targets/bard1/), [BIRC3](https://onco.cc/targets/birc3/), [BIRC5](https://onco.cc/targets/birc5/), [BRAF](https://onco.cc/targets/braf/), [CBL](https://onco.cc/targets/cbl/), [CBLB](https://onco.cc/targets/cblb/), [CCDC6](https://onco.cc/targets/ccdc6/), [CCND2](https://onco.cc/targets/ccnd2/), [CCND3](https://onco.cc/targets/ccnd3/), [CD137 (4-1BB, TNFRSF9)](https://onco.cc/targets/cd137/), [CD209](https://onco.cc/targets/cd209/), [CD73 / adenosine axis](https://onco.cc/targets/cd73-adenosine/), [CD74](https://onco.cc/targets/cd74/), [CD80 (B7-1)](https://onco.cc/targets/cd80/), [CD96](https://onco.cc/targets/cd96/), [CDH10](https://onco.cc/targets/cdh10/), [CDKN2A](https://onco.cc/targets/cdkn2a/), [CEACAM5](https://onco.cc/targets/ceacam5/), [CIC](https://onco.cc/targets/cic/), [Claudin 6](https://onco.cc/targets/cldn6/), [CLIP1](https://onco.cc/targets/clip1/), [CMTR2](https://onco.cc/targets/cmtr2/), [CRKL](https://onco.cc/targets/crkl/), [CRLF2](https://onco.cc/targets/crlf2/), [CTLA-4](https://onco.cc/targets/ctla4/), [CTNNA2](https://onco.cc/targets/ctnna2/), [CTNND2](https://onco.cc/targets/ctnnd2/), [CUL3](https://onco.cc/targets/cul3/), [CX3CL1](https://onco.cc/targets/cx3cl1/), [DCAF12L2](https://onco.cc/targets/dcaf12l2/), [DDR2 receptor kinase](https://onco.cc/targets/ddr2/), [DICER1](https://onco.cc/targets/dicer1/), [DNA polymerase alpha (POLA1)](https://onco.cc/targets/pola1/), [DROSHA](https://onco.cc/targets/drosha/), [EBF1](https://onco.cc/targets/ebf1/), [EGFR](https://onco.cc/targets/egfr/), [EML4](https://onco.cc/targets/eml4/), [EPHA7](https://onco.cc/targets/epha7/), [ERCC1](https://onco.cc/targets/ercc1/), [ERCC2](https://onco.cc/targets/ercc2/), [ERCC3](https://onco.cc/targets/ercc3/), [ERCC4](https://onco.cc/targets/ercc4/), [ERCC5](https://onco.cc/targets/ercc5/), [EREG](https://onco.cc/targets/ereg/), [ERRFI1](https://onco.cc/targets/errfi1/), [ETS2](https://onco.cc/targets/ets2/), [FAK (PTK2)](https://onco.cc/targets/fak/), [FAM135B](https://onco.cc/targets/fam135b/), [FGFR1](https://onco.cc/targets/fgfr1/), [FLCN](https://onco.cc/targets/flcn/), [Folate receptor alpha](https://onco.cc/targets/folr1/), [FOXO1](https://onco.cc/targets/foxo1/), [GART (trifunctional purine synthesis enzyme)](https://onco.cc/targets/gart/), [GNAQ](https://onco.cc/targets/gnaq/), [HER2](https://onco.cc/targets/her2/), [HER3](https://onco.cc/targets/her3/), [HER4 (ERBB4)](https://onco.cc/targets/erbb4/), [HGF](https://onco.cc/targets/hgf/), [IGF-1 receptor (IGF1R)](https://onco.cc/targets/igf1r/), [IRS4](https://onco.cc/targets/irs4/), [JAK3](https://onco.cc/targets/jak3/), [KEAP1](https://onco.cc/targets/keap1/), [KIF5B](https://onco.cc/targets/kif5b/), [KLF5](https://onco.cc/targets/klf5/), [KMT2B](https://onco.cc/targets/kmt2b/), [KRAS](https://onco.cc/targets/kras/), [LATS2](https://onco.cc/targets/lats2/), [LRIG3](https://onco.cc/targets/lrig3/), [MACC1](https://onco.cc/targets/macc1/), [MAML2](https://onco.cc/targets/maml2/), [MAPK1](https://onco.cc/targets/mapk1/), [MB21D2](https://onco.cc/targets/mb21d2/), [MEK1/2](https://onco.cc/targets/mek/), [MET](https://onco.cc/targets/met/), [MGA](https://onco.cc/targets/mga/), [MIR21](https://onco.cc/targets/mir21/), [MUC6](https://onco.cc/targets/muc6/), [NCOA2](https://onco.cc/targets/ncoa2/), [NF1 (neurofibromin)](https://onco.cc/targets/nf1/), [NFE2L2](https://onco.cc/targets/nfe2l2/), [NFKBIE](https://onco.cc/targets/nfkbie/), [NIPBL](https://onco.cc/targets/nipbl/), [NKG2A (KLRC1)](https://onco.cc/targets/klrc1/), [NKX2-1](https://onco.cc/targets/nkx2-1/), [NRG1](https://onco.cc/targets/nrg1/), [NRK](https://onco.cc/targets/nrk/), [NSD3](https://onco.cc/targets/nsd3/), [NTRK](https://onco.cc/targets/ntrk/), [NUP98](https://onco.cc/targets/nup98/), [NUTM1](https://onco.cc/targets/nutm1/), [PABPC1](https://onco.cc/targets/pabpc1/), [PAPPA2](https://onco.cc/targets/pappa2/), [PARP4](https://onco.cc/targets/parp4/), [PBK](https://onco.cc/targets/pbk/), [PBX1](https://onco.cc/targets/pbx1/), [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [PER3](https://onco.cc/targets/per3/), [PHF6](https://onco.cc/targets/phf6/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/), [PIM1](https://onco.cc/targets/pim1/), [POLE4](https://onco.cc/targets/pole4/), [PPM1D](https://onco.cc/targets/ppm1d/), [PRAME](https://onco.cc/targets/prame/), [PRKDC](https://onco.cc/targets/prkdc/), [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/), [PSPC1](https://onco.cc/targets/pspc1/), [PTPRF](https://onco.cc/targets/ptprf/), [PTPRK](https://onco.cc/targets/ptprk/), [PXDNL](https://onco.cc/targets/pxdnl/), [RAD21](https://onco.cc/targets/rad21/), [RANBP2](https://onco.cc/targets/ranbp2/), [RASA1](https://onco.cc/targets/rasa1/), [RB1](https://onco.cc/targets/rb1/), [RBM10](https://onco.cc/targets/rbm10/), [RBM15](https://onco.cc/targets/rbm15/), [RET](https://onco.cc/targets/ret/), [RGPD3](https://onco.cc/targets/rgpd3/), [RGS7](https://onco.cc/targets/rgs7/), [RHPN2](https://onco.cc/targets/rhpn2/), [Ribonucleotide reductase (RRM1)](https://onco.cc/targets/rrm1/), [RICTOR](https://onco.cc/targets/rictor/), [RIT1](https://onco.cc/targets/rit1/), [RON receptor (MST1R)](https://onco.cc/targets/ron/), [ROS1](https://onco.cc/targets/ros1/), [RPL5](https://onco.cc/targets/rpl5/), [SCN8A](https://onco.cc/targets/scn8a/), [SDC4](https://onco.cc/targets/sdc4/), [SETD1B](https://onco.cc/targets/setd1b/), [SHP2 (PTPN11)](https://onco.cc/targets/shp2/), [SLC34A2](https://onco.cc/targets/slc34a2/), [SMARCA4](https://onco.cc/targets/smarca4/), [SOX2](https://onco.cc/targets/sox2/), [STK11](https://onco.cc/targets/stk11/), [SUSD2](https://onco.cc/targets/susd2/), [TCF3](https://onco.cc/targets/tcf3/), [TFRC](https://onco.cc/targets/tfrc/), [TIGIT](https://onco.cc/targets/tigit/), [TIM-3](https://onco.cc/targets/tim3/), [TNC](https://onco.cc/targets/tnc/), [TP53](https://onco.cc/targets/tp53/), [TPM3](https://onco.cc/targets/tpm3/), [TROP2](https://onco.cc/targets/trop2/), [TSC1](https://onco.cc/targets/tsc1/), [TTF1](https://onco.cc/targets/ttf1/), [Tubulin (microtubules)](https://onco.cc/targets/tubulin/), [USP8](https://onco.cc/targets/usp8/), [VAV1](https://onco.cc/targets/vav1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/), [VISTA](https://onco.cc/targets/vista/), [XRCC1](https://onco.cc/targets/xrcc1/), [ZEB1](https://onco.cc/targets/zeb1/), [ZMYM3](https://onco.cc/targets/zmym3/), [ZNF395](https://onco.cc/targets/znf395/), [ZNF750](https://onco.cc/targets/znf750/)
- drugs: [ABBV-706](https://onco.cc/drugs/abbv-706/), [ABSK061](https://onco.cc/drugs/absk061/), [Acasunlimab](https://onco.cc/drugs/acasunlimab/), [Adagrasib](https://onco.cc/drugs/adagrasib/), [Afatinib](https://onco.cc/drugs/afatinib/), [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/), [AK117](https://onco.cc/drugs/ak117/), [AK146D1](https://onco.cc/drugs/ak146d1/), [AL8326](https://onco.cc/drugs/al8326/), [Alectinib](https://onco.cc/drugs/alectinib/), [Amivantamab](https://onco.cc/drugs/amivantamab/), [Amrubicin](https://onco.cc/drugs/amrubicin/), [AMT-116](https://onco.cc/drugs/amt-116/), [Anlotinib](https://onco.cc/drugs/anlotinib/), [Anvumetostat](https://onco.cc/drugs/anvumetostat/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Atigotatug](https://onco.cc/drugs/atigotatug/), [AU-007](https://onco.cc/drugs/au-007/), [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [AZD7789](https://onco.cc/drugs/azd7789/), [BA3071](https://onco.cc/drugs/ba3071/), [Befotertinib](https://onco.cc/drugs/befotertinib/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Binimetinib](https://onco.cc/drugs/binimetinib/), [BNT324](https://onco.cc/drugs/bnt324/), [Boserolimab](https://onco.cc/drugs/boserolimab/), [Brenetafusp](https://onco.cc/drugs/brenetafusp/), [Brigatinib](https://onco.cc/drugs/brigatinib/), [Budigalimab](https://onco.cc/drugs/budigalimab/), [Calderasib](https://onco.cc/drugs/calderasib/), [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Capmatinib](https://onco.cc/drugs/capmatinib/), [Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Ceritinib](https://onco.cc/drugs/ceritinib/), [Cetrelimab](https://onco.cc/drugs/cetrelimab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [cobas EGFR Mutation Test v2](https://onco.cc/drugs/cobas-egfr-mutation-test/), [Cobolimab](https://onco.cc/drugs/cobolimab/), [Crizotinib](https://onco.cc/drugs/crizotinib/), [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Dabrafenib + trametinib](https://onco.cc/drugs/dabrafenib-trametinib/), [Dacomitinib](https://onco.cc/drugs/dacomitinib/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Denosumab](https://onco.cc/drugs/denosumab/), [Divarasib](https://onco.cc/drugs/divarasib/), [DJI136](https://onco.cc/drugs/dji136/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Domvanalimab](https://onco.cc/drugs/domvanalimab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [EIK1001](https://onco.cc/drugs/eik1001/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Encorafenib](https://onco.cc/drugs/encorafenib/), [Ensartinib](https://onco.cc/drugs/ensartinib/), [Entrectinib](https://onco.cc/drugs/entrectinib/), [ENV-501](https://onco.cc/drugs/env-501/), [EP0031](https://onco.cc/drugs/ep0031/), [Erlotinib](https://onco.cc/drugs/erlotinib/), [Fulzerasib](https://onco.cc/drugs/fulzerasib/), [Furmonertinib](https://onco.cc/drugs/furmonertinib/), [Garsorasib](https://onco.cc/drugs/garsorasib/), [Gefitinib](https://onco.cc/drugs/gefitinib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [GFH375](https://onco.cc/drugs/gfh375/), [Glecirasib](https://onco.cc/drugs/glecirasib/), [Glumetinib](https://onco.cc/drugs/glumetinib/), [Gotistobart](https://onco.cc/drugs/gotistobart/), [Guardant Reveal](https://onco.cc/drugs/guardant-reveal/), [Guardant360 CDx](https://onco.cc/drugs/guardant360-cdx/), [HB0036](https://onco.cc/drugs/hb0036/), [HLX26](https://onco.cc/drugs/hlx26/), [HLX43](https://onco.cc/drugs/hlx43/), [HMBD-001](https://onco.cc/drugs/hmbd-001/), [HS-20093](https://onco.cc/drugs/hs-20093/), [HS-20117](https://onco.cc/drugs/hs-20117/), [IBI363](https://onco.cc/drugs/ibi363/), [Icotinib](https://onco.cc/drugs/icotinib/), [IN10018](https://onco.cc/drugs/in10018/), [Iniparib](https://onco.cc/drugs/iniparib/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Iruplinalkib](https://onco.cc/drugs/iruplinalkib/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [JDQ443](https://onco.cc/drugs/jdq443/), [JK08](https://onco.cc/drugs/jk08/), [JMT101](https://onco.cc/drugs/jmt101/), [JMT203](https://onco.cc/drugs/jmt203/), [JS111](https://onco.cc/drugs/js111/), [JYP0015](https://onco.cc/drugs/jyp0015/), [KL-A167](https://onco.cc/drugs/kl-a167/), [Larotrectinib](https://onco.cc/drugs/larotrectinib/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Lifileucel](https://onco.cc/drugs/lifileucel/), [Limertinib](https://onco.cc/drugs/limertinib/), [Livmoniplimab](https://onco.cc/drugs/livmoniplimab/), [Lorlatinib](https://onco.cc/drugs/lorlatinib/), [LP-184](https://onco.cc/drugs/lp-184/), [Mavrostobart](https://onco.cc/drugs/mavrostobart/), [MCLA-129](https://onco.cc/drugs/mcla-129/), [MI Cancer Seek](https://onco.cc/drugs/caris-mi-cancer-seek/), [Mobocertinib](https://onco.cc/drugs/mobocertinib/), [Monalizumab](https://onco.cc/drugs/monalizumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Navlimetostat](https://onco.cc/drugs/navlimetostat/), [Necitumumab](https://onco.cc/drugs/necitumumab/), [Nedaplatin](https://onco.cc/drugs/nedaplatin/), [Neladalkib](https://onco.cc/drugs/neladalkib/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/), [Olmutinib](https://onco.cc/drugs/olmutinib/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Olvimulogene nanivacirepvec](https://onco.cc/drugs/olvimulogene-nanivacirepvec/), [Oncomine Dx Target Test](https://onco.cc/drugs/oncomine-dx-target-test/), [Optellum Virtual Nodule Clinic](https://onco.cc/drugs/optellum-virtual-nodule-clinic/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/), [OR502](https://onco.cc/drugs/or502/), [OSE2101](https://onco.cc/drugs/ose2101/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pafolacianine](https://onco.cc/drugs/pafolacianine/), [Palacaparib](https://onco.cc/drugs/palacaparib/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/), [PD-L1 IHC 22C3 pharmDx](https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/), [Peluntamig](https://onco.cc/drugs/peluntamig/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [PF-07248144](https://onco.cc/drugs/pf-07248144/), [PF-08046054](https://onco.cc/drugs/pf-08046054/), [PF-08634404](https://onco.cc/drugs/pf-08634404/), [PM8002](https://onco.cc/drugs/pm8002/), [Porfimer sodium](https://onco.cc/drugs/porfimer-sodium/), [Pralsetinib](https://onco.cc/drugs/pralsetinib/), [QL1706](https://onco.cc/drugs/ql1706/), [QL2107](https://onco.cc/drugs/ql2107/), [QLC5508](https://onco.cc/drugs/qlc5508/), [Quemliclustat](https://onco.cc/drugs/quemliclustat/), [RaDaR](https://onco.cc/drugs/radar-mrd/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [RC148](https://onco.cc/drugs/rc148/), [Recombinant human endostatin](https://onco.cc/drugs/recombinant-human-endostatin/), [REGN7075](https://onco.cc/drugs/regn7075/), [Repotrectinib](https://onco.cc/drugs/repotrectinib/), [Resolution ctDx FIRST](https://onco.cc/drugs/resolution-ctdx-first/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Roginolisib](https://onco.cc/drugs/roginolisib/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/), [Saruparib](https://onco.cc/drugs/saruparib/), [Savolitinib](https://onco.cc/drugs/savolitinib/), [SCTB14](https://onco.cc/drugs/sctb14/), [SCTB41](https://onco.cc/drugs/sctb41/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/), [Setidegrasib](https://onco.cc/drugs/setidegrasib/), [Sevabertinib](https://onco.cc/drugs/sevabertinib/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [SHR-A2009](https://onco.cc/drugs/shr-a2009/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/), [SI-B001](https://onco.cc/drugs/si-b001/), [Signatera](https://onco.cc/drugs/signatera/), [Silevertinib](https://onco.cc/drugs/silevertinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Sitneprotafib](https://onco.cc/drugs/sitneprotafib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [SSGJ-706](https://onco.cc/drugs/ssgj-706/), [Sugemalimab](https://onco.cc/drugs/sugemalimab/), [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/), [SYS6010](https://onco.cc/drugs/sys6010/), [T3011](https://onco.cc/drugs/t3011/), [TAK-928](https://onco.cc/drugs/tak-928/), [Talc (intrapleural)](https://onco.cc/drugs/talc-sclerosant/), [Taletrectinib](https://onco.cc/drugs/taletrectinib/), [Telisotuzumab adizutecan](https://onco.cc/drugs/telisotuzumab-adizutecan/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [Tepotinib](https://onco.cc/drugs/tepotinib/), [TGRX-326](https://onco.cc/drugs/tgrx-326/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/), [Tilatamig samrotecan](https://onco.cc/drugs/tilatamig-samrotecan/), [Tiragolumab](https://onco.cc/drugs/tiragolumab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [TNG260](https://onco.cc/drugs/tng260/), [TNG456](https://onco.cc/drugs/tng456/), [TNG462](https://onco.cc/drugs/tng462/), [TNO155](https://onco.cc/drugs/tno155/), [TQB2102](https://onco.cc/drugs/tqb2102/), [TQB2450](https://onco.cc/drugs/tqb2450/), [TQB6411](https://onco.cc/drugs/tqb6411/), [Trametinib](https://onco.cc/drugs/trametinib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/), [TRI-611](https://onco.cc/drugs/tri-611/), [Tusamitamab ravtansine](https://onco.cc/drugs/tusamitamab-ravtansine/), [TY-9591](https://onco.cc/drugs/ty-9591/), [Uliledlimab](https://onco.cc/drugs/uliledlimab/), [Upifitamab rilsodotin](https://onco.cc/drugs/upifitamab-rilsodotin/), [Vebreltinib](https://onco.cc/drugs/vebreltinib/), [VENTANA PD-L1 (SP142) Assay](https://onco.cc/drugs/ventana-pd-l1-sp142/), [VENTANA PD-L1 (SP263) Assay](https://onco.cc/drugs/ventana-pd-l1-sp263/), [Vibostolimab](https://onco.cc/drugs/vibostolimab/), [Vindesine](https://onco.cc/drugs/vindesine/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/), [Vistusertib](https://onco.cc/drugs/vistusertib/), [VRN110755](https://onco.cc/drugs/vrn110755/), [VS-7375](https://onco.cc/drugs/vs-7375/), [XNW27011](https://onco.cc/drugs/xnw27011/), [YL201](https://onco.cc/drugs/yl201/), [YL202](https://onco.cc/drugs/yl202/), [Zenocutuzumab](https://onco.cc/drugs/zenocutuzumab/), [ZG006](https://onco.cc/drugs/zg006/), [Zidesamtinib](https://onco.cc/drugs/zidesamtinib/), [Zipalertinib](https://onco.cc/drugs/zipalertinib/), [ZL-1310](https://onco.cc/drugs/zl-1310/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/), [Zongertinib](https://onco.cc/drugs/zongertinib/)
- companies: [A2 Biotherapeutics](https://onco.cc/companies/a2-biotherapeutics/), [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Achieve Life Sciences (formerly OncoGenex)](https://onco.cc/companies/achieve-life-sciences/), [Actinium Pharmaceuticals](https://onco.cc/companies/actinium-pharmaceuticals/), [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/), [Adventris Pharmaceuticals](https://onco.cc/companies/adventris-pharmaceuticals/), [Agennix](https://onco.cc/companies/agennix/), [Akeso](https://onco.cc/companies/akeso/), [Amgen](https://onco.cc/companies/amgen/), [Amphista Therapeutics](https://onco.cc/companies/amphista-therapeutics/), [Anbogen Therapeutics](https://onco.cc/companies/anbogen-therapeutics/), [ANGLE plc](https://onco.cc/companies/angle-plc/), [Aosaikang Pharmaceutical](https://onco.cc/companies/aosaikang-pharmaceutical/), [AP Biosciences](https://onco.cc/companies/ap-biosciences/), [Apollomics](https://onco.cc/companies/apollomics/), [Arcus Biosciences](https://onco.cc/companies/arcus-biosciences/), [ArriVent BioPharma](https://onco.cc/companies/arrivent/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/), [Bayer](https://onco.cc/companies/bayer/), [BeyondSpring Pharmaceuticals](https://onco.cc/companies/beyondspring/), [Biodesix](https://onco.cc/companies/biodesix/), [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Black Diamond Therapeutics](https://onco.cc/companies/black-diamond-therapeutics/), [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/), [BridgeBio Oncology Therapeutics](https://onco.cc/companies/bridgebio-oncology-therapeutics/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/), [CatalYm](https://onco.cc/companies/catalym/), [CellSight Technologies](https://onco.cc/companies/cellsight-technologies/), [Celltrion](https://onco.cc/companies/celltrion/), [Chinese Thoracic Oncology Group](https://onco.cc/companies/ctong/), [Chugai Pharmaceutical](https://onco.cc/companies/chugai/), [CivaTech Oncology](https://onco.cc/companies/civatech-oncology/), [Cofactor Genomics](https://onco.cc/companies/cofactor-genomics/), [Compass Therapeutics](https://onco.cc/companies/compass-therapeutics/), [D3 Bio (Wuxi)](https://onco.cc/companies/d3-bio-wuxi/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [DELFI Diagnostics](https://onco.cc/companies/delfi-diagnostics/), [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/), [Dizal Pharmaceutical](https://onco.cc/companies/dizal/), [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/), [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/), [Elpiscience (Suzhou) Biopharma](https://onco.cc/companies/elpiscience-suzhou-biopharma/), [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/), [EpicentRx](https://onco.cc/companies/epicentrx/), [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/), [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/), [Frontier Medicines](https://onco.cc/companies/frontier-medicines/), [Fujirebio](https://onco.cc/companies/fujirebio/), [Genelux](https://onco.cc/companies/genelux/), [Genprex](https://onco.cc/companies/genprex/), [GI Innovation](https://onco.cc/companies/gi-innovation/), [GTx](https://onco.cc/companies/gtx/), [GV20 Therapeutics](https://onco.cc/companies/gv20-therapeutics/), [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/), [Haystack Oncology](https://onco.cc/companies/haystack-oncology/), [Imagene AI](https://onco.cc/companies/imagene-ai/), [Immuneering](https://onco.cc/companies/immuneering/), [Immunovaccine (IMV)](https://onco.cc/companies/immunovaccine/), [Immutep](https://onco.cc/companies/immutep/), [Inivata](https://onco.cc/companies/inivata/), [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/), [InxMed](https://onco.cc/companies/inxmed/), [iOnctura](https://onco.cc/companies/ionctura/), [Ionis Pharmaceuticals](https://onco.cc/companies/ionis/), [Japan Clinical Oncology Group (JCOG)](https://onco.cc/companies/jcog/), [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [Kanvas Biosciences](https://onco.cc/companies/kanvas-biosciences/), [Korean Cancer Study Group](https://onco.cc/companies/kcsg/), [Krystal Biotech](https://onco.cc/companies/krystal-biotech/), [Kumquat Biosciences](https://onco.cc/companies/kumquat-biosciences/), [Lucence](https://onco.cc/companies/lucence/), [Lunit](https://onco.cc/companies/lunit/), [mAbxience Research S.L.](https://onco.cc/companies/mabxience-research-s-l/), [Maia Biotechnology](https://onco.cc/companies/maia-biotechnology/), [MBrace Therapeutics](https://onco.cc/companies/mbrace-therapeutics/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/), [Molecular Partners](https://onco.cc/companies/molecular-partners/), [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/), [Mythic Therapeutics](https://onco.cc/companies/mythic-therapeutics/), [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/), [Nerviano Medical Sciences](https://onco.cc/companies/nerviano-medical-sciences/), [Novartis](https://onco.cc/companies/novartis/), [Nucleix](https://onco.cc/companies/nucleix/), [Nuvalent](https://onco.cc/companies/nuvalent/), [Nuvation Bio](https://onco.cc/companies/nuvation-bio/), [Obsidian Therapeutics](https://onco.cc/companies/obsidian-therapeutics/), [On Target Laboratories](https://onco.cc/companies/on-target-laboratories/), [Onc.AI](https://onco.cc/companies/onc-ai/), [OncoC4](https://onco.cc/companies/oncoc4/), [OncoHost](https://onco.cc/companies/oncohost/), [Optellum](https://onco.cc/companies/optellum/), [ORIC Pharmaceuticals](https://onco.cc/companies/oric-pharmaceuticals/), [Orion, Orion Pharma](https://onco.cc/companies/orion-orion-pharma/), [OSE Immunotherapeutics](https://onco.cc/companies/ose-immunotherapeutics/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Owlstone Medical](https://onco.cc/companies/owlstone-medical/), [P-Cure](https://onco.cc/companies/p-cure/), [Pathos AI](https://onco.cc/companies/pathos-ai/), [Peregrine Pharmaceuticals (now Avid Bioservices)](https://onco.cc/companies/peregrine-avid/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Proxygen](https://onco.cc/companies/proxygen/), [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/), [Radiopharm Theranostics](https://onco.cc/companies/radiopharm-theranostics/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Salubris Biotherapeutics](https://onco.cc/companies/salubris-biotherapeutics/), [Shanghai Fosun Pharmaceutical Industrial Development](https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/), [Shanghai Juncell Therapeutics](https://onco.cc/companies/shanghai-juncell-therapeutics/), [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/), [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/), [Sinocelltech](https://onco.cc/companies/sinocelltech/), [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/), [STCube](https://onco.cc/companies/stcube/), [Strata Oncology](https://onco.cc/companies/strata-oncology/), [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/), [SunHo Biopharmaceutical](https://onco.cc/companies/sunho-biopharmaceutical/), [Suzhou BlueHorse Therapeutics](https://onco.cc/companies/suzhou-bluehorse-therapeutics/), [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/), [Telik](https://onco.cc/companies/telik/), [Transgene](https://onco.cc/companies/transgene/), [Triana Biomedicines](https://onco.cc/companies/triana-biomedicines/), [TROG Cancer Research](https://onco.cc/companies/trog/), [Tubulis (Gilead)](https://onco.cc/companies/tubulis/), [TYK Medicines](https://onco.cc/companies/tyk-medicines/), [Vergent Bioscience](https://onco.cc/companies/vergent-bioscience/), [VolitionRx](https://onco.cc/companies/volitionrx/), [Vyriad](https://onco.cc/companies/vyriad/), [Wayshine Biopharm](https://onco.cc/companies/wayshine-biopharm/), [West Japan Oncology Group](https://onco.cc/companies/wjog/), [XACT Robotics](https://onco.cc/companies/xact-robotics/), [Xcovery](https://onco.cc/companies/xcovery/), [Xilio Therapeutics](https://onco.cc/companies/xilio-therapeutics/), [Xuanzhu Biopharmaceutical](https://onco.cc/companies/xuanzhu-biopharmaceutical/), [Yuhan Corporation](https://onco.cc/companies/yuhan/)
- institutions: [Aichi Cancer Center](https://onco.cc/institutions/aichi-cancer-center/), [Apollo Hospitals (Apollo Cancer Centres)](https://onco.cc/institutions/apollo-hospitals/), [Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service](https://onco.cc/institutions/auckland-city-hospital/), [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/), [Cancer Center Clínica Universidad de Navarra / CIMA](https://onco.cc/institutions/cun-navarra/), [Cancer Council Australia](https://onco.cc/institutions/cancer-council-australia/), [Cancer Grand Challenges](https://onco.cc/institutions/cancer-grand-challenges/), [Cancer Research UK Manchester Institute](https://onco.cc/institutions/cruk-manchester-institute/), [Centre hospitalier de l'Université de Montréal (CHUM)](https://onco.cc/institutions/chum/), [Centro Nacional de Investigaciones Oncológicas (CNIO)](https://onco.cc/institutions/cnio/), [Chang Gung Memorial Hospital](https://onco.cc/institutions/chang-gung-memorial-hospital/), [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/), [Guangdong Provincial People's Hospital](https://onco.cc/institutions/guangdong-provincial-peoples-hospital/), [Harold C. Simmons Comprehensive Cancer Center, UT Southwestern](https://onco.cc/institutions/utsw-simmons/), [HealthCare Global Enterprises](https://onco.cc/institutions/hcg/), [Henan Cancer Hospital](https://onco.cc/institutions/henan-cancer-hospital/), [Hokkaido University Hospital](https://onco.cc/institutions/hokkaido-university-hospital/), [Hospital Universitario 12 de Octubre](https://onco.cc/institutions/12-de-octubre/), [Hunan Cancer Hospital](https://onco.cc/institutions/hunan-cancer-hospital/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://onco.cc/institutions/inselspital-bern/), [Instituto Alexander Fleming](https://onco.cc/institutions/instituto-alexander-fleming/), [Instituto Nacional de Câncer (INCA)](https://onco.cc/institutions/inca-brazil/), [Instituto Nacional de Cancerología (Mexico)](https://onco.cc/institutions/incan-mexico/), [Instituto Nacional de Oncología y Radiobiología (INOR)](https://onco.cc/institutions/inor-cuba/), [International Association for the Study of Lung Cancer](https://onco.cc/institutions/iaslc/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [IRCCS Humanitas Research Hospital](https://onco.cc/institutions/humanitas/), [IRCCS Regina Elena National Cancer Institute](https://onco.cc/institutions/regina-elena-rome/), [Istanbul University Institute of Oncology](https://onco.cc/institutions/istanbul-oncology-institute/), [Istituto Nazionale Tumori IRCCS Fondazione G. Pascale](https://onco.cc/institutions/pascale-naples/), [Jiangsu Cancer Hospital](https://onco.cc/institutions/jiangsu-cancer-hospital/), [King Hussein Cancer Center](https://onco.cc/institutions/khcc/), [Koo Foundation Sun Yat-Sen Cancer Center](https://onco.cc/institutions/koo-foundation-sun-yat-sen-cancer-center/), [Kyoto University Hospital](https://onco.cc/institutions/kyoto-university-hospital/), [Kyushu University Hospital](https://onco.cc/institutions/kyushu-university-hospital/), [Laura and Isaac Perlmutter Cancer Center at NYU Langone Health](https://onco.cc/institutions/nyu-perlmutter/), [Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne](https://onco.cc/institutions/chuv-lausanne/), [Leeds Cancer Centre, St James's University Hospital](https://onco.cc/institutions/leeds-cancer-centre/), [Leicester Cancer Research Centre / University Hospitals of Leicester](https://onco.cc/institutions/leicester-cancer-research-centre/), [Liverpool Heart and Chest Hospital NHS Foundation Trust](https://onco.cc/institutions/liverpool-heart-and-chest/), [LungenClinic Grosshansdorf](https://onco.cc/institutions/lungenclinic-grosshansdorf/), [Maria Skłodowska-Curie National Research Institute of Oncology](https://onco.cc/institutions/nio-warsaw/), [Markey Cancer Center, University of Kentucky](https://onco.cc/institutions/kentucky-markey/), [Max Healthcare (Max Institute of Cancer Care)](https://onco.cc/institutions/max-healthcare/), [Mount Vernon Cancer Centre](https://onco.cc/institutions/mount-vernon-cancer-centre/), [MUSC Hollings Cancer Center](https://onco.cc/institutions/musc-hollings/), [National Cancer Center Hospital East](https://onco.cc/institutions/ncc-hospital-east/), [National Cancer Center Korea](https://onco.cc/institutions/ncc-korea/), [National Cancer Centre Singapore](https://onco.cc/institutions/nccs/), [National Cancer Registry Programme (ICMR-NINE, Bengaluru)](https://onco.cc/institutions/icmr-ncrp/), [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/), [National University Hospital / National University Cancer Institute, Singapore](https://onco.cc/institutions/nuh-ncis/), [nationales Netzwerk Genomische Medizin Lungenkrebs](https://onco.cc/institutions/nngm/), [Newcastle Cancer Centre / Northern Centre for Cancer Care](https://onco.cc/institutions/newcastle-cancer-centre/), [Nottingham University Hospitals Cancer Centre (City Hospital)](https://onco.cc/institutions/nottingham-cancer-centre/), [Osaka International Cancer Institute](https://onco.cc/institutions/osaka-international-cancer-institute/), [Prince of Wales Hospital / Chinese University of Hong Kong](https://onco.cc/institutions/prince-of-wales-hospital-cuhk/), [Queen Mary Hospital / University of Hong Kong](https://onco.cc/institutions/queen-mary-hospital-hku/), [Rajiv Gandhi Cancer Institute and Research Centre](https://onco.cc/institutions/rgci/), [Rigshospitalet, Copenhagen University Hospital](https://onco.cc/institutions/rigshospitalet/), [Roy Castle Lung Cancer Foundation](https://onco.cc/institutions/roy-castle-lung-cancer-foundation/), [Royal Papworth Hospital NHS Foundation Trust](https://onco.cc/institutions/royal-papworth/), [Seoul National University Hospital](https://onco.cc/institutions/snuh/), [Shandong Cancer Hospital and Institute](https://onco.cc/institutions/shandong-cancer-hospital/), [Shanghai Chest Hospital](https://onco.cc/institutions/shanghai-chest-hospital/), [Shanghai Pulmonary Hospital](https://onco.cc/institutions/shanghai-pulmonary-hospital/), [Shizuoka Cancer Center](https://onco.cc/institutions/shizuoka-cancer-center/), [Stand Up To Cancer](https://onco.cc/institutions/stand-up-to-cancer/), [Taipei Veterans General Hospital](https://onco.cc/institutions/taipei-veterans-general-hospital/), [The Christie NHS Foundation Trust](https://onco.cc/institutions/the-christie/), [The Francis Crick Institute](https://onco.cc/institutions/francis-crick/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/), [Tohoku University Hospital](https://onco.cc/institutions/tohoku-university-hospital/), [UC Davis Comprehensive Cancer Center](https://onco.cc/institutions/uc-davis-cancer/), [Uniklinik Köln (CIO)](https://onco.cc/institutions/uniklinik-koeln/), [Union Hospital, Tongji Medical College](https://onco.cc/institutions/union-hospital-wuhan/), [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/), [University Hospital Basel / Tumour Centre](https://onco.cc/institutions/usb-basel/), [University Hospital Southampton / Centre for Cancer Immunology](https://onco.cc/institutions/southampton-cancer/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/), [University Hospitals Birmingham / University of Birmingham Cancer Research Centre](https://onco.cc/institutions/birmingham-cancer-centre/), [University of Colorado Cancer Center](https://onco.cc/institutions/colorado-cancer-center/), [University of Hawai'i Cancer Center](https://onco.cc/institutions/hawaii-cancer-center/), [Vanderbilt-Ingram Cancer Center](https://onco.cc/institutions/vanderbilt-ingram/), [VCU Massey Comprehensive Cancer Center](https://onco.cc/institutions/vcu-massey/), [Velindre Cancer Centre](https://onco.cc/institutions/velindre-cardiff/), [Vietnam National Cancer Hospital (K Hospital)](https://onco.cc/institutions/k-hospital-hanoi/), [Winship Cancer Institute of Emory University](https://onco.cc/institutions/emory-winship/), [Yale Cancer Center / Smilow Cancer Hospital](https://onco.cc/institutions/yale-cancer-center/), [Zhejiang Cancer Hospital](https://onco.cc/institutions/zhejiang-cancer-hospital/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/), [Cancer cachexia](https://onco.cc/pathways/cachexia-biology/), [Chemical carcinogenesis - receptor activation](https://onco.cc/pathways/chemical-carcinogenesis-receptor-activation/), [Chromosomal instability & aneuploidy](https://onco.cc/pathways/chromosomal-instability/), [Clonal evolution & minimal residual disease](https://onco.cc/pathways/clonal-evolution/), [Drug-tolerant persister cells](https://onco.cc/pathways/drug-tolerant-persisters/), [Epithelial-mesenchymal transition & drug efflux](https://onco.cc/pathways/emt/), [FGF / FGFR signalling](https://onco.cc/pathways/fgfr-signalling/), [Field cancerisation](https://onco.cc/pathways/field-cancerisation/), [KEAP1-NRF2 antioxidant pathway](https://onco.cc/pathways/keap1-nrf2/), [Lineage plasticity & neuroendocrine transformation](https://onco.cc/pathways/lineage-plasticity-neuroendocrine/), [Mutagenesis & mutational signatures](https://onco.cc/pathways/mutagenesis-signatures/), [MYC](https://onco.cc/pathways/myc/), [Non-small cell lung cancer (KEGG map)](https://onco.cc/pathways/nsclc-signalling/), [Notch signalling](https://onco.cc/pathways/notch/), [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [PI3K / AKT / mTOR](https://onco.cc/pathways/pi3k-akt-mtor/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/), [Resistance routes: how a blocked pathway comes back](https://onco.cc/pathways/resistance-routes-map/), [Small cell lung cancer (KEGG map)](https://onco.cc/pathways/sclc-signalling/), [SWI/SNF chromatin remodelling](https://onco.cc/pathways/swi-snf-chromatin/), [T-cell exhaustion](https://onco.cc/pathways/t-cell-exhaustion/), [The blood-brain barrier & brain metastasis](https://onco.cc/pathways/blood-brain-barrier-metastasis/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/), [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- terms: [Adenocarcinoma](https://onco.cc/terms/adenocarcinoma/), [Age, smoking and inherited predisposition: what the treatment risk is added to](https://onco.cc/terms/rejuv-second-age-smoking-and-inherited-risk/), [Amplification](https://onco.cc/terms/amplification/), [Anaemia](https://onco.cc/terms/anaemia/), [Asbestos](https://onco.cc/terms/asbestos/), [Biopsy](https://onco.cc/terms/biopsy/), [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [BRAF V600E mutation](https://onco.cc/terms/braf-v600-mutation/), [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Bronchoscopy (EBUS, robotic navigation)](https://onco.cc/terms/bronchoscopy/), [Cancer cachexia](https://onco.cc/terms/cachexia/), [Cancer-related fatigue (tiredness)](https://onco.cc/terms/cancer-related-fatigue/), [CDKN2A/B homozygous deletion](https://onco.cc/terms/cdkn2a-homozygous-deletion/), [Cell-free DNA (cfDNA)](https://onco.cc/terms/cfdna/), [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Clonal evolution and the ecological view of cancer](https://onco.cc/terms/clonal-evolution-theory/), [Consolidation therapy](https://onco.cc/terms/consolidation-therapy/), [Copy number alteration (CNA)](https://onco.cc/terms/copy-number-variation-term/), [Cross-resistance](https://onco.cc/terms/cross-resistance/), [Curative intent vs palliative intent](https://onco.cc/terms/curative-intent/), [Differentiation](https://onco.cc/terms/differentiation/), [Driver mutation](https://onco.cc/terms/driver-mutation/), [Drug resistance (primary and acquired)](https://onco.cc/terms/resistance/), [EGFR C797S](https://onco.cc/terms/c797s/), [EGFR exon 19 deletion & L858R](https://onco.cc/terms/egfr-exon19-l858r/), [EGFR exon 20 insertion](https://onco.cc/terms/egfr-exon20-insertion/), [EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)](https://onco.cc/terms/egfr-mutation-subtypes/), [Endobronchial ultrasound (EBUS-TBNA)](https://onco.cc/terms/ebus-tbna/), [FISH / ISH (in situ hybridisation)](https://onco.cc/terms/fish/), [Gene amplification and copy-number change](https://onco.cc/terms/gene-amplification/), [Gene fusion](https://onco.cc/terms/gene-fusion/), [Germline vs somatic mutations](https://onco.cc/terms/germline-vs-somatic/), [Haemoptysis (coughing up blood)](https://onco.cc/terms/haemoptysis/), [HER2-positive (IHC 3+ or ISH-amplified)](https://onco.cc/terms/her2-positive/), [Histologic transformation](https://onco.cc/terms/histologic-transformation/), [Histology](https://onco.cc/terms/histology/), [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [Immune exclusion](https://onco.cc/terms/immune-exclusion/), [Immune surveillance and cancer immunoediting](https://onco.cc/terms/immune-surveillance-immunoediting/), [Immune-mediated colitis and diarrhoea](https://onco.cc/terms/immune-colitis/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/), [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Lobectomy](https://onco.cc/terms/lobectomy/), [Lung cancer after chest radiotherapy and after alkylating chemotherapy](https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/), [Lung cancer drugs in England: what NICE has recommended](https://onco.cc/terms/lung-uk-drug-access/), [Lung cancer in never-smokers](https://onco.cc/terms/never-smoker-lung-cancer/), [Lung cancer: the failed and stopped programmes, and why](https://onco.cc/terms/lung-failed-programmes/), [Lung-RADS and nodule reporting](https://onco.cc/terms/lung-rads/), [Maintenance therapy](https://onco.cc/terms/maintenance-therapy/), [Malignant pleural effusion](https://onco.cc/terms/malignant-pleural-effusion/), [Malignant pleural effusion and ascites](https://onco.cc/terms/pleural-effusion/), [Mediastinal lymph node stations](https://onco.cc/terms/mediastinal-lymph-node-stations/), [Mediastinum](https://onco.cc/terms/mediastinum/), [MET amplification (bypass resistance)](https://onco.cc/terms/met-amplification/), [MET exon 14 skipping mutation](https://onco.cc/terms/met-exon-14-skipping/), [Mutational signature](https://onco.cc/terms/mutational-signature/), [Neoantigen](https://onco.cc/terms/neoantigen/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Oligometastatic disease](https://onco.cc/terms/oligometastatic/), [Oligoprogression](https://onco.cc/terms/oligoprogression/), [Pack-year](https://onco.cc/terms/pack-year/), [Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain](https://onco.cc/terms/lung-palliation-breathlessness-effusion-obstruction/), [Pancoast (superior sulcus) tumour](https://onco.cc/terms/pancoast-tumour/), [Performance status (ECOG, Karnofsky)](https://onco.cc/terms/performance-status/), [Pleura](https://onco.cc/terms/pleura/), [Pleurodesis and indwelling pleural catheter](https://onco.cc/terms/pleurodesis/), [Pneumonectomy](https://onco.cc/terms/pneumonectomy/), [Pneumonitis](https://onco.cc/terms/pneumonitis/), [Pulmonary nodule](https://onco.cc/terms/pulmonary-nodule/), [Radiation pneumonitis and lung fibrosis](https://onco.cc/terms/radiation-pneumonitis/), [Radon](https://onco.cc/terms/radon/), [Resectability in lung cancer](https://onco.cc/terms/resectability-lung-cancer/), [Resectable, borderline resectable and unresectable](https://onco.cc/terms/resectability/), [Segmentectomy (sublobar resection)](https://onco.cc/terms/segmentectomy/), [Somatic mutations from exome and genome sequencing (WXS, WGS)](https://onco.cc/terms/somatic-mutations-wxs-wgs/), [Spread through air spaces (STAS)](https://onco.cc/terms/spread-through-air-spaces/), [Squamous cell carcinoma](https://onco.cc/terms/squamous-cell-carcinoma/), [STK11 / KEAP1 co-mutations](https://onco.cc/terms/stk11-keap1/), [Stopping smoking](https://onco.cc/terms/smoking-cessation/), [Sublobar resection (segmentectomy and wedge)](https://onco.cc/terms/sublobar-resection/), [Superior vena cava obstruction](https://onco.cc/terms/superior-vena-cava-obstruction/), [Targeted lung health check](https://onco.cc/terms/targeted-lung-health-check/), [TERT promoter mutation](https://onco.cc/terms/tert-promoter/), [TNM 9: what changed in lung cancer staging](https://onco.cc/terms/tnm-9-lung-cancer/), [TNM staging](https://onco.cc/terms/tnm-staging/), [TTF-1 and p40 (how lung histology is decided)](https://onco.cc/terms/ttf1-p40/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/), [Tumour proportion score (TPS)](https://onco.cc/terms/tps/), [Tumour-agnostic (tissue-agnostic) approval](https://onco.cc/terms/tumour-agnostic/), [Variant of uncertain significance (VUS)](https://onco.cc/terms/vus/), [Wild-type (WT)](https://onco.cc/terms/wild-type/)
- trials: [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://onco.cc/trials/nct07189871/), [A 2-part Phase 1/2 Open-label Trial on ODM-212](https://onco.cc/trials/nct07563738/), [A Beta-only IL-2 ImmunoTherapY Study](https://onco.cc/trials/nct05086692/), [A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)](https://onco.cc/trials/nct07190248/), [A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations](https://onco.cc/trials/nct06735391/), [A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)](https://onco.cc/trials/nct06698042/), [A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study](https://onco.cc/trials/nct07609251/), [A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer](https://onco.cc/trials/nct05913089/), [A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients](https://onco.cc/trials/nct05787613/), [A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ](https://onco.cc/trials/nct07513376/), [A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)](https://onco.cc/trials/nct07554339/), [A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality](https://onco.cc/trials/nct06496490/), [A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors](https://onco.cc/trials/nct06581419/), [A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ](https://onco.cc/trials/nct07111520/), [A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)](https://onco.cc/trials/nct05989542/), [A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation](https://onco.cc/trials/nct07231068/), [A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07439094/), [A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations](https://onco.cc/trials/nct07629960/), [A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors](https://onco.cc/trials/nct04686682/), [A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07459751/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06868277/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N](https://onco.cc/trials/nct06627647/), [A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s](https://onco.cc/trials/nct06692738/), [A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung](https://onco.cc/trials/nct05984277/), [A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC](https://onco.cc/trials/nct05211895/), [A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05221840/), [A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection](https://onco.cc/trials/nct05120349/), [A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors](https://onco.cc/trials/nct07636785/), [A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ](https://onco.cc/trials/nct06956690/), [A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol](https://onco.cc/trials/nct06427941/), [A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC](https://onco.cc/trials/nct07491497/), [A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors](https://onco.cc/trials/nct07020221/), [A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC](https://onco.cc/trials/nct05394831/), [A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04036682/), [A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946](https://onco.cc/trials/nct06616766/), [A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05585320/), [A Phase 2 Clinical Study of ABSK061 and ABSK043](https://onco.cc/trials/nct06632262/), [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib](https://onco.cc/trials/nct06668103/), [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib](https://onco.cc/trials/nct07164170/), [A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer](https://onco.cc/trials/nct07133425/), [A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)](https://onco.cc/trials/nct06593522/), [A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC](https://onco.cc/trials/nct06246110/), [A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC](https://onco.cc/trials/nct07562581/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07659782/), [A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors](https://onco.cc/trials/nct06695845/), [A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation](https://onco.cc/trials/nct07174908/), [A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins](https://onco.cc/trials/nct07182682/), [A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer](https://onco.cc/trials/nct05902988/), [A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib](https://onco.cc/trials/nct07362940/), [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06848699/), [A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC](https://onco.cc/trials/nct05543330/), [A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers](https://onco.cc/trials/nct05910827/), [A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer](https://onco.cc/trials/nct07253142/), [A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06907615/), [A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07283198/), [A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)](https://onco.cc/trials/nct06295432/), [A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07489716/), [A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct06015503/), [A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07669779/), [A Phase II Study of GC101 in NSCLC](https://onco.cc/trials/nct07560111/), [A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo](https://onco.cc/trials/nct07824882/), [A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv](https://onco.cc/trials/nct06962865/), [A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients](https://onco.cc/trials/nct07171606/), [A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC](https://onco.cc/trials/nct07269782/), [A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer](https://onco.cc/trials/nct07444437/), [A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients](https://onco.cc/trials/nct06335355/), [A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients](https://onco.cc/trials/nct06564324/), [A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy](https://onco.cc/trials/nct05450692/), [A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S](https://onco.cc/trials/nct07464327/), [A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients](https://onco.cc/trials/nct05870319/), [A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）](https://onco.cc/trials/nct06612151/), [A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct04951635/), [A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC](https://onco.cc/trials/nct06908304/), [A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C](https://onco.cc/trials/nct06564844/), [A Phase IIII Study of AL8326 in Small Cell Lung Cancer](https://onco.cc/trials/nct06247605/), [A Platform Study in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06996782/), [A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct05565378/), [A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati](https://onco.cc/trials/nct07809256/), [A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung](https://onco.cc/trials/nct05085028/), [A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05654454/), [A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07365319/), [A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC](https://onco.cc/trials/nct05246514/), [A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance](https://onco.cc/trials/nct06822543/), [A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s](https://onco.cc/trials/nct07640789/), [A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU](https://onco.cc/trials/nct06382129/), [A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)](https://onco.cc/trials/nct06382116/), [A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC](https://onco.cc/trials/nct04606771/), [A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07217301/), [A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer](https://onco.cc/trials/nct04641754/), [A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f](https://onco.cc/trials/nct07739186/), [A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors](https://onco.cc/trials/nct06244771/), [A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases](https://onco.cc/trials/nct06970639/), [A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi](https://onco.cc/trials/nct05920356/), [A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip](https://onco.cc/trials/nct06793215/), [A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C](https://onco.cc/trials/nct05170204/), [A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05417321/), [A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par](https://onco.cc/trials/nct05789082/), [A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)](https://onco.cc/trials/nct05526755/), [A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05592626/), [A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene](https://onco.cc/trials/nct04395677/), [A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer](https://onco.cc/trials/nct02152631/), [A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)](https://onco.cc/trials/nct06875310/), [A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC](https://onco.cc/trials/nct06617416/), [A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer](https://onco.cc/trials/nct05990127/), [A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07623356/), [A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05488314/), [A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure](https://onco.cc/trials/nct04988295/), [A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07227025/), [A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667076/), [A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05498428/), [A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05047250/), [A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04995523/), [A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06472076/), [A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations](https://onco.cc/trials/nct06706076/), [A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ](https://onco.cc/trials/nct05880706/), [A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU](https://onco.cc/trials/nct07642024/), [A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06498986/), [A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas](https://onco.cc/trials/nct06838273/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ](https://onco.cc/trials/nct06475300/), [A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors](https://onco.cc/trials/nct05949619/), [A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS](https://onco.cc/trials/nct07264816/), [A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer](https://onco.cc/trials/nct06114511/), [A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct07178795/), [A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct04895709/), [A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)](https://onco.cc/trials/nct06345729/), [A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce](https://onco.cc/trials/nct06465329/), [A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig](https://onco.cc/trials/nct07412262/), [A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions](https://onco.cc/trials/nct04538664/), [A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05908734/), [A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)](https://onco.cc/trials/nct05859217/), [A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)](https://onco.cc/trials/nct05460273/), [A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2](https://onco.cc/trials/nct06003231/), [A Study of DM005 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06515990/), [A Study of DS-3939a in Participants With Solid Tumors](https://onco.cc/trials/nct07739966/), [A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors](https://onco.cc/trials/nct04440735/), [A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients](https://onco.cc/trials/nct03706690/), [A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)](https://onco.cc/trials/nct05668988/), [A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies](https://onco.cc/trials/nct05443126/), [A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct06623136/), [A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct06119581/), [A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07172802/), [A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct05669430/), [A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06172478/), [A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06147570/), [A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06417008/), [A Study of IBI363 in Subjects with Advanced Solid Malignancies](https://onco.cc/trials/nct06281678/), [A Study of IDP-001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07602842/), [A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (](https://onco.cc/trials/nct06077760/), [A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)](https://onco.cc/trials/nct07221474/), [A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)](https://onco.cc/trials/nct06780085/), [A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07535463/), [A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China](https://onco.cc/trials/nct05009329/), [A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1](https://onco.cc/trials/nct05276726/), [A Study of JMT203 in Patients With Cancer Cachexia](https://onco.cc/trials/nct06868849/), [A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667908/), [A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)](https://onco.cc/trials/nct05388669/), [A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05297890/), [A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma](https://onco.cc/trials/nct05456256/), [A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06954246/), [A Study of MT-4561 in Patients With Various Advanced Solid Tumors](https://onco.cc/trials/nct06943521/), [A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04302025/), [A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)](https://onco.cc/trials/nct06855771/), [A Study of NDI 1150-101 in Patients With Solid Tumors](https://onco.cc/trials/nct05128487/), [A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC](https://onco.cc/trials/nct07586202/), [A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer](https://onco.cc/trials/nct04025879/), [A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct03800134/), [A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07098338/), [A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents](https://onco.cc/trials/nct06090266/), [A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S](https://onco.cc/trials/nct04351555/), [A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC](https://onco.cc/trials/nct07058519/), [A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol](https://onco.cc/trials/nct06099782/), [A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)](https://onco.cc/trials/nct06623422/), [A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34](https://onco.cc/trials/nct06731907/), [A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection](https://onco.cc/trials/nct05487391/), [A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer](https://onco.cc/trials/nct05690945/), [A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE](https://onco.cc/trials/nct02411448/), [A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04077099/), [A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)](https://onco.cc/trials/nct06140836/), [A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct06879717/), [A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET](https://onco.cc/trials/nct03157128/), [A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04819100/), [A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer](https://onco.cc/trials/nct06012435/), [A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC](https://onco.cc/trials/nct06754930/), [A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations](https://onco.cc/trials/nct06430437/), [A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct07183189/), [A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC](https://onco.cc/trials/nct06671379/), [A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06589778/), [A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct07229729/), [A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05949606/), [A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other](https://onco.cc/trials/nct05956587/), [A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-](https://onco.cc/trials/nct05816252/), [A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan](https://onco.cc/trials/nct06670196/), [A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P](https://onco.cc/trials/nct06711900/), [A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06448312/), [A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07622186/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)](https://onco.cc/trials/nct05722015/), [A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension](https://onco.cc/trials/nct06212752/), [A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct02716116/), [A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05635708/), [A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct06644768/), [A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive](https://onco.cc/trials/nct06930794/), [A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07699328/), [A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04996121/), [A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors](https://onco.cc/trials/nct07208773/), [A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07739758/), [A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07169994/), [A Study of YL202 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07202364/), [A Study of YL202 in Selected Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06107686/), [A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)](https://onco.cc/trials/nct02912949/), [A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.](https://onco.cc/trials/nct05967689/), [A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)](https://onco.cc/trials/dllevate/), [A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07155187/), [A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ](https://onco.cc/trials/nct06568939/), [A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07005102/), [A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm](https://onco.cc/trials/nct06312137/), [A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan](https://onco.cc/trials/nct07756645/), [A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct06631989/), [A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct06868485/), [A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer](https://onco.cc/trials/nct04931654/), [A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu](https://onco.cc/trials/nct07680764/), [A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection](https://onco.cc/trials/nct07128199/), [A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06311721/), [A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer](https://onco.cc/trials/nct06939595/), [A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L](https://onco.cc/trials/nct06687369/), [A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation](https://onco.cc/trials/nct07566052/), [A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion](https://onco.cc/trials/nct07063745/), [A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)](https://onco.cc/trials/nct06646276/), [A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases](https://onco.cc/trials/nct04603807/), [A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N](https://onco.cc/trials/nct06561386/), [A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous](https://onco.cc/trials/nct06847334/), [A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s](https://onco.cc/trials/nct06348199/), [A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr](https://onco.cc/trials/nct07005336/), [A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06984588/), [A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer](https://onco.cc/trials/nct07365241/), [A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04765059/), [A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC](https://onco.cc/trials/nct06754644/), [A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation](https://onco.cc/trials/nct07668752/), [A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell](https://onco.cc/trials/nct07361497/), [A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC](https://onco.cc/trials/nct07206498/), [A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer](https://onco.cc/trials/nct05318573/), [A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese](https://onco.cc/trials/nct07541170/), [A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N](https://onco.cc/trials/nct06829459/), [A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct03178552/), [A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct06010329/), [A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P](https://onco.cc/trials/nct07361510/), [A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct06682793/), [A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct05736731/), [A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression](https://onco.cc/trials/nct06051695/), [A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07362459/), [A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance](https://onco.cc/trials/nct07223047/), [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations](https://onco.cc/trials/nct07610798/), [A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre](https://onco.cc/trials/nct06946797/), [A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors](https://onco.cc/trials/nct06747585/), [A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors](https://onco.cc/trials/nct07169734/), [A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07538804/), [A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy](https://onco.cc/trials/nct05941897/), [A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth](https://onco.cc/trials/nct05801029/), [A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other](https://onco.cc/trials/nct05081609/), [A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07115043/), [A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ](https://onco.cc/trials/nct06606847/), [A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer](https://onco.cc/trials/nct05361174/), [A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan](https://onco.cc/trials/nct06417814/), [A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N](https://onco.cc/trials/nct05048797/), [A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS](https://onco.cc/trials/nct06008093/), [A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies](https://onco.cc/trials/nct05473156/), [A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07154290/), [A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-4/), [A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small](https://onco.cc/trials/nct05785767/), [A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma](https://onco.cc/trials/nct06452277/), [A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment](https://onco.cc/trials/nct07601048/), [A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05482568/), [A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC](https://onco.cc/trials/nct04316364/), [A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06512051/), [A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ](https://onco.cc/trials/nct03390686/), [A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ](https://onco.cc/trials/nct05557591/), [A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ](https://onco.cc/trials/nct05800015/), [A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth](https://onco.cc/trials/nct06161441/), [ADAURA](https://onco.cc/trials/adaura/), [Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth](https://onco.cc/trials/nct06616584/), [Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease](https://onco.cc/trials/nct06141070/), [Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden](https://onco.cc/trials/nct07715396/), [Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations](https://onco.cc/trials/nct06041776/), [Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer](https://onco.cc/trials/nct00576914/), [Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct01124253/), [AENEAS](https://onco.cc/trials/aeneas/), [Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)](https://onco.cc/trials/aurora/), [AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05904379/), [AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05840016/), [AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor](https://onco.cc/trials/nct07158840/), [AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC](https://onco.cc/trials/nct05247684/), [AK129 Combination Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct06943820/), [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [ALEX](https://onco.cc/trials/alex/), [ALINA](https://onco.cc/trials/alina/), [ALKOVE-1](https://onco.cc/trials/alkove-1/), [Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct04616209/), [Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations](https://onco.cc/trials/nct04687241/), [ALTA](https://onco.cc/trials/alta/), [ALTA-1L](https://onco.cc/trials/alta-1l/), [ALTER 0303](https://onco.cc/trials/alter-0303/), [AMPLE](https://onco.cc/trials/ample/), [AMT-116 in Combination With AK112 in Patients With Lung Cancer](https://onco.cc/trials/nct07590531/), [An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06693336/), [An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07371663/), [Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct03637816/), [Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations](https://onco.cc/trials/nct07336732/), [Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer](https://onco.cc/trials/nct04322617/), [Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas](https://onco.cc/trials/nct05841472/), [ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct01360554/), [ARCHER 1050](https://onco.cc/trials/nct01774721/), [ARROW (thyroid cohorts)](https://onco.cc/trials/arrow-thyroid/), [ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct06498479/), [ASCEND-4](https://onco.cc/trials/nct01828099/), [ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct04143607/), [ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy](https://onco.cc/trials/nct07109531/), [Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral](https://onco.cc/trials/nct01933932/), [Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)](https://onco.cc/trials/nct03974022/), [Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04270591/), [Atamparib in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07374419/), [Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy](https://onco.cc/trials/nct03977194/), [Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut](https://onco.cc/trials/nct04923906/), [Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct04614103/), [Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme](https://onco.cc/trials/nct02568267/), [Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations](https://onco.cc/trials/nct04579380/), [Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab](https://onco.cc/trials/nct07486817/), [Beamion LUNG-1](https://onco.cc/trials/beamion-lung-1/), [Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment](https://onco.cc/trials/nct06151574/), [Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati](https://onco.cc/trials/nct07195695/), [BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06205706/), [Big Lung Trial](https://onco.cc/trials/big-lung-trial/), [Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets](https://onco.cc/trials/nct05317858/), [Boosting Osimertinib Blood Brain Barrier Penetration](https://onco.cc/trials/nct07485452/), [BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors](https://onco.cc/trials/nct05120271/), [BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05393466/), [CALGB 140503 (Alliance)](https://onco.cc/trials/calgb-140503/), [CameL](https://onco.cc/trials/camel/), [CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC](https://onco.cc/trials/nct04495153/), [CHART](https://onco.cc/trials/chart-lung/), [CheckMate 017](https://onco.cc/trials/checkmate-017/), [CheckMate 026](https://onco.cc/trials/checkmate-026/), [CheckMate 057](https://onco.cc/trials/checkmate-057/), [CheckMate 227](https://onco.cc/trials/checkmate-227/), [CheckMate 816](https://onco.cc/trials/checkmate-816/), [CheckMate 9LA](https://onco.cc/trials/checkmate-9la/), [Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial](https://onco.cc/trials/nct06096844/), [CHISEL (TROG 09.02)](https://onco.cc/trials/chisel/), [CHRYSALIS](https://onco.cc/trials/chrysalis/), [Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06896890/), [Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective,](https://onco.cc/trials/nct07197853/), [Clinical Study of 18F-Alfatide Injection PET/CT](https://onco.cc/trials/nct06416852/), [Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1](https://onco.cc/trials/nct06767514/), [Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06828757/), [Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis](https://onco.cc/trials/nct06961188/), [Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct05009836/), [Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In](https://onco.cc/trials/nct06745908/), [CodeBreaK 200](https://onco.cc/trials/codebreak-200/), [Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery](https://onco.cc/trials/nct00005838/), [Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation](https://onco.cc/trials/nct05609578/), [Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04379635/), [CROWN](https://onco.cc/trials/crown/), [ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)](https://onco.cc/trials/nct06951646/), [D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar](https://onco.cc/trials/nct06300177/), [Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)](https://onco.cc/trials/nct05555732/), [De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction](https://onco.cc/trials/nct05255302/), [DESTINY-Lung01](https://onco.cc/trials/destiny-lung01/), [DESTINY-Lung02](https://onco.cc/trials/destiny-lung02/), [Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors](https://onco.cc/trials/nct04140500/), [Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy](https://onco.cc/trials/nct05431270/), [Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas](https://onco.cc/trials/nct05751798/), [Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC](https://onco.cc/trials/nct07467863/), [Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC](https://onco.cc/trials/nct07641023/), [Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer](https://onco.cc/trials/nct04499053/), [Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation](https://onco.cc/trials/nct03833154/), [Dutch Bone Metastasis Study](https://onco.cc/trials/dutch-bone-metastasis-study/), [DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)](https://onco.cc/trials/nct07070440/), [DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)](https://onco.cc/trials/nct06276283/), [Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ](https://onco.cc/trials/nct06463665/), [Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer](https://onco.cc/trials/nct07276789/), [Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion](https://onco.cc/trials/nct05466149/), [Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy](https://onco.cc/trials/nct06607796/), [Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients](https://onco.cc/trials/nct06028633/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy](https://onco.cc/trials/nct04655976/), [EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study](https://onco.cc/trials/nct06486142/), [EMPOWER-Lung 1](https://onco.cc/trials/empower-lung-1/), [Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib](https://onco.cc/trials/nct06120140/), [Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study](https://onco.cc/trials/nct06775483/), [Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas](https://onco.cc/trials/nct06872541/), [eXalt3](https://onco.cc/trials/nct02767804/), [EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.](https://onco.cc/trials/nct06448572/), [FHND9041 Versus Afatinib for Non-small Cell Lung Cancer](https://onco.cc/trials/nct06759857/), [FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC](https://onco.cc/trials/nct06303505/), [Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation](https://onco.cc/trials/nct06956001/), [First in Human Study of TUB-030 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06657222/), [First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI](https://onco.cc/trials/nct05920135/), [First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations](https://onco.cc/trials/nct06043817/), [First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b](https://onco.cc/trials/nct03319628/), [First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.](https://onco.cc/trials/nct06840782/), [First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07355205/), [FLAURA](https://onco.cc/trials/flaura/), [FLAURA2](https://onco.cc/trials/flaura2/), [FURLONG](https://onco.cc/trials/furlong/), [Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)](https://onco.cc/trials/gefitinib-chemo-tmh/), [GEMSTONE-302](https://onco.cc/trials/gemstone-302/), [GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors](https://onco.cc/trials/nct04083599/), [GEOMETRY mono-1](https://onco.cc/trials/geometry-mono-1/), [GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07554859/), [GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors](https://onco.cc/trials/nct04977453/), [Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct06198907/), [HARMONi-2](https://onco.cc/trials/harmoni-2/), [HARMONi-3](https://onco.cc/trials/harmoni-3/), [HARMONi-A](https://onco.cc/trials/harmoni-a/), [HC010 in First-line PD-L1 Positive Advanced NSCLC Patients](https://onco.cc/trials/nct07169552/), [HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04619004/), [HERTHENA-Lung02](https://onco.cc/trials/herthena-lung02/), [Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct02448992/), [IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small](https://onco.cc/trials/nct07122687/), [ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07452224/), [Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG](https://onco.cc/trials/nct06107374/), [Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer](https://onco.cc/trials/nct06840704/), [Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer](https://onco.cc/trials/nct05522660/), [IMpower110](https://onco.cc/trials/impower110/), [IMpower150](https://onco.cc/trials/impower150/), [IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC](https://onco.cc/trials/nct05994131/), [Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS](https://onco.cc/trials/nct05688280/), [Intratumoral N17350 in Advanced Solid Tumors](https://onco.cc/trials/nct07339176/), [Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC](https://onco.cc/trials/nct07718243/), [IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)](https://onco.cc/trials/nct05742607/), [Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC](https://onco.cc/trials/nct07405190/), [Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06928389/), [JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation](https://onco.cc/trials/nct06416410/), [JCOG0403](https://onco.cc/trials/jcog0403/), [JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations](https://onco.cc/trials/nct06391944/), [JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy](https://onco.cc/trials/jrosg-99-1/), [JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）](https://onco.cc/trials/nct06505837/), [JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations](https://onco.cc/trials/nct06940401/), [KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)](https://onco.cc/trials/nct04165070/), [KEYNOTE-010](https://onco.cc/trials/keynote-010/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [KEYNOTE-407](https://onco.cc/trials/keynote-407/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/), [Krascendo 1](https://onco.cc/trials/krascendo-1/), [KRYSTAL-12](https://onco.cc/trials/krystal-12/), [LAURA](https://onco.cc/trials/laura/), [LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib](https://onco.cc/trials/nct01828112/), [LIBRETTO-431](https://onco.cc/trials/libretto-431/), [Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC](https://onco.cc/trials/nct07050043/), [Low-dose olanzapine for cancer anorexia (Tata Memorial)](https://onco.cc/trials/olanzapine-appetite-tmh/), [LUME-Lung 1](https://onco.cc/trials/lume-lung-1/), [LUMINOSITY](https://onco.cc/trials/luminosity/), [LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC](https://onco.cc/trials/nct06216301/), [Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI](https://onco.cc/trials/nct07355231/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [Lung-MAP S1400I: nivolumab with or without ipilimumab](https://onco.cc/trials/lung-map-s1400i/), [Lung-MAP S1800A: ramucirumab plus pembrolizumab](https://onco.cc/trials/lung-map-s1800a/), [Lung-SEARCH](https://onco.cc/trials/lungsearch/), [Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07149649/), [MARIPOSA](https://onco.cc/trials/mariposa/), [Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07477808/), [MERMAID-1](https://onco.cc/trials/mermaid-1/), [MERMAID-2](https://onco.cc/trials/mermaid-2/), [MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)](https://onco.cc/trials/nct07431827/), [Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients](https://onco.cc/trials/nct02802540/), [Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07150663/), [National Lung Matrix Trial](https://onco.cc/trials/national-lung-matrix-trial/), [NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct07224152/), [Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC](https://onco.cc/trials/nct06765109/), [Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer](https://onco.cc/trials/nct07306624/), [Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer](https://onco.cc/trials/nct05116462/), [Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct05061550/), [Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients](https://onco.cc/trials/nct03916627/), [Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer](https://onco.cc/trials/nct05765877/), [NLST & NELSON (low-dose CT screening)](https://onco.cc/trials/nlst-nelson/), [OAK](https://onco.cc/trials/oak/), [Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT](https://onco.cc/trials/nct05236946/), [Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study](https://onco.cc/trials/nct03381274/), [Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA](https://onco.cc/trials/nct03228277/), [ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors](https://onco.cc/trials/nct05671510/), [Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot](https://onco.cc/trials/nct07001618/), [ORIENT-11](https://onco.cc/trials/orient-11/), [PACIFIC](https://onco.cc/trials/pacific/), [PACIFIC-2](https://onco.cc/trials/pacific-2/), [PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct03774732/), [PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %](https://onco.cc/trials/nct04547504/), [Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287](https://onco.cc/trials/nct06422143/), [Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors](https://onco.cc/trials/nct03647163/), [Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms](https://onco.cc/trials/nct05987956/), [Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)](https://onco.cc/trials/nct06430866/), [PHAROS](https://onco.cc/trials/pharos/), [Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina](https://onco.cc/trials/nct04868877/), [Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients](https://onco.cc/trials/nct05074810/), [Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct05435248/), [Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations](https://onco.cc/trials/nct05256290/), [Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct07151040/), [Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer](https://onco.cc/trials/nct03907852/), [Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation](https://onco.cc/trials/nct05288205/), [Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.](https://onco.cc/trials/nct07148128/), [Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067](https://onco.cc/trials/nct04787042/), [Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06162572/), [Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients](https://onco.cc/trials/nct05532696/), [Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)](https://onco.cc/trials/nct03944772/), [Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment](https://onco.cc/trials/nct05363280/), [Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G](https://onco.cc/trials/nct04613596/), [Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)](https://onco.cc/trials/nct07154706/), [Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor](https://onco.cc/trials/nct06105021/), [Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)](https://onco.cc/trials/nct04152499/), [Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors](https://onco.cc/trials/nct05024214/), [Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects](https://onco.cc/trials/nct07175220/), [Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC](https://onco.cc/trials/nct07603791/), [Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung](https://onco.cc/trials/nct05195632/), [Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto](https://onco.cc/trials/nct07329322/), [Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets](https://onco.cc/trials/nct07234877/), [Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung](https://onco.cc/trials/nct02485652/), [Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy](https://onco.cc/trials/nct02444819/), [Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy](https://onco.cc/trials/nct03334617/), [Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No](https://onco.cc/trials/nct07383116/), [Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct02453282/), [Phase III Study of AK112 for NSCLC Patients](https://onco.cc/trials/nct06396065/), [Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti](https://onco.cc/trials/nct07291037/), [Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC](https://onco.cc/trials/nct06123754/), [Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act](https://onco.cc/trials/nct07829549/), [Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva](https://onco.cc/trials/nct07170995/), [Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)](https://onco.cc/trials/fleteo/), [Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）](https://onco.cc/trials/nct06927986/), [Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L](https://onco.cc/trials/nct06350097/), [Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct05687266/), [Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥](https://onco.cc/trials/nct06357533/), [Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07416994/), [Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct05358249/), [PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer](https://onco.cc/trials/nct06616532/), [Ponsegromab phase 2 in cancer cachexia](https://onco.cc/trials/ponsegromab-phase-2/), [Premedication to Reduce Amivantamab Associated Infusion Related Reactions](https://onco.cc/trials/nct05663866/), [Primary Radiotherapy In MEtastatic Lung Cancer](https://onco.cc/trials/nct07135882/), [Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC](https://onco.cc/trials/nct06745882/), [QLS5132 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07453394/), [Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib](https://onco.cc/trials/nct04486833/), [QUARTZ](https://onco.cc/trials/quartz/), [QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors](https://onco.cc/trials/nct03228667/), [Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors](https://onco.cc/trials/nct06814496/), [Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer](https://onco.cc/trials/nct06686771/), [RAPA-201 Therapy of Solid Tumors](https://onco.cc/trials/nct05144698/), [RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)](https://onco.cc/trials/sqnsclc/), [Retifanlimab and Ruxolitinib In Solid Malignancies](https://onco.cc/trials/nct07219576/), [REVEL](https://onco.cc/trials/revel/), [REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)](https://onco.cc/trials/nct05973773/), [Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other](https://onco.cc/trials/nct07468071/), [ROMANA 1 and ROMANA 2](https://onco.cc/trials/romana-1-2/), [RTOG 0617](https://onco.cc/trials/rtog-0617/), [SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer](https://onco.cc/trials/sabr-comet/), [Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases](https://onco.cc/trials/nct06401824/), [Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P](https://onco.cc/trials/nct06170788/), [Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct06074588/), [Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A](https://onco.cc/trials/nct06305754/), [Safety and Efficacy of OBX-115 in Advanced Solid Tumors](https://onco.cc/trials/nct06060613/), [Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer](https://onco.cc/trials/nct05117242/), [Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che](https://onco.cc/trials/nct06841055/), [Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss](https://onco.cc/trials/nct06810544/), [Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer](https://onco.cc/trials/nct06712316/), [Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC](https://onco.cc/trials/nct03970746/), [Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC](https://onco.cc/trials/nct04140526/), [SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients](https://onco.cc/trials/nct04154956/), [Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment](https://onco.cc/trials/nct05261399/), [SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07662395/), [Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI](https://onco.cc/trials/nct07181499/), [SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations](https://onco.cc/trials/nct06080776/), [SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.](https://onco.cc/trials/nct05020457/), [SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05020769/), [SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.](https://onco.cc/trials/nct05351788/), [SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07697586/), [SL-28 for Advanced Solid Tumours](https://onco.cc/trials/nct07341737/), [SOHO-01](https://onco.cc/trials/soho-01/), [Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer](https://onco.cc/trials/nct05501665/), [SQUIRE](https://onco.cc/trials/squire/), [SSGJ-707 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06980272/), [Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC](https://onco.cc/trials/nct05278052/), [Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）](https://onco.cc/trials/nct07076693/), [Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06523673/), [Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction](https://onco.cc/trials/nct07132190/), [Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression](https://onco.cc/trials/nct04180371/), [Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies](https://onco.cc/trials/nct04561362/), [Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients](https://onco.cc/trials/nct04632758/), [Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct07189455/), [Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer](https://onco.cc/trials/nct04736173/), [Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur](https://onco.cc/trials/nct03836352/), [Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)](https://onco.cc/trials/nct06710132/), [Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca](https://onco.cc/trials/nct05267626/), [Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct04644068/), [Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06706713/), [Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct06514027/), [Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC](https://onco.cc/trials/nct06569420/), [Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07030257/), [Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)](https://onco.cc/trials/nct06881784/), [Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab](https://onco.cc/trials/nct05215340/), [Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05651022/), [Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).](https://onco.cc/trials/nct03164616/), [Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)](https://onco.cc/trials/nct03003962/), [Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)](https://onco.cc/trials/nct02542293/), [Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)](https://onco.cc/trials/nct03775486/), [Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.](https://onco.cc/trials/nct05445843/), [Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ](https://onco.cc/trials/nct06726265/), [Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06128551/), [Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs](https://onco.cc/trials/nct06567015/), [Study of GV20-0251 in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct07070518/), [Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen](https://onco.cc/trials/nct04198766/), [Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer](https://onco.cc/trials/nct05403385/), [Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy](https://onco.cc/trials/nct07100080/), [Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct05132075/), [Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct04699188/), [Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer](https://onco.cc/trials/nct05620134/), [Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct06895031/), [Study of LP-184 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05933265/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors](https://onco.cc/trials/nct04930432/), [Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation](https://onco.cc/trials/nct05737706/), [Study of NEO-201 in Solid Tumors Expansion Cohorts](https://onco.cc/trials/nct03476681/), [Study of Novel Treatment Combinations in Patients With Lung Cancer](https://onco.cc/trials/nct05633667/), [Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06890598/), [Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)](https://onco.cc/trials/nct07079475/), [Study of Oral MRT-2359 in Selected Cancer Patients](https://onco.cc/trials/nct05546268/), [Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)](https://onco.cc/trials/nct05609968/), [Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan](https://onco.cc/trials/nct04956692/), [Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu](https://onco.cc/trials/nct07777822/), [Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)](https://onco.cc/trials/nct04380636/), [Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct04786964/), [Study of PF-07248144 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04606446/), [Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors](https://onco.cc/trials/nct07397338/), [Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC](https://onco.cc/trials/nct06162221/), [Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities](https://onco.cc/trials/nct04683250/), [Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct05379985/), [Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors](https://onco.cc/trials/nct06040541/), [Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer](https://onco.cc/trials/nct03937154/), [Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)](https://onco.cc/trials/nct03767348/), [Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05089734/), [Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05186974/), [Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers](https://onco.cc/trials/nct05098132/), [Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas](https://onco.cc/trials/nct05565417/), [Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can](https://onco.cc/trials/nct06704620/), [Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors](https://onco.cc/trials/nct05887492/), [Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer](https://onco.cc/trials/nct06899126/), [Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer](https://onco.cc/trials/nct07806773/), [Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06903377/), [Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05985655/), [Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,](https://onco.cc/trials/nct05925530/), [Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [](https://onco.cc/trials/nct02486718/), [Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm](https://onco.cc/trials/nct05546866/), [Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer](https://onco.cc/trials/nct07288177/), [Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct05607550/), [Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations](https://onco.cc/trials/nct06772623/), [Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-2/), [Study to Evaluate D-1553 in Subjects With Solid Tumors](https://onco.cc/trials/nct04585035/), [Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W](https://onco.cc/trials/nct07185997/), [Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05168566/), [Study With Various Immunotherapy Treatments in Participants With Lung Cancer](https://onco.cc/trials/nct05676931/), [SUMMIT (lung health check study)](https://onco.cc/trials/summit-lung/), [Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)](https://onco.cc/trials/nct05712902/), [SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer](https://onco.cc/trials/nct07322341/), [SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05570825/), [Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/symbiotic-lung-01/), [Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/symbiotic-lung-04/), [Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC](https://onco.cc/trials/nct07489066/), [Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers](https://onco.cc/trials/nct07227298/), [SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST](https://onco.cc/trials/nct07633873/), [SYS6090 Combination Therapy in Advanced Lung Cancer](https://onco.cc/trials/nct07472647/), [Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients](https://onco.cc/trials/nct02579564/), [T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer](https://onco.cc/trials/nct06045767/), [TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct04129502/), [Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC](https://onco.cc/trials/nct04919811/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/), [TeliMET NSCLC-01](https://onco.cc/trials/telimet-nsclc-01/), [Test-retest Evaluation of [18F]F-AraG PET](https://onco.cc/trials/nct06084806/), [Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain](https://onco.cc/trials/nct06500455/), [Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial](https://onco.cc/trials/nct06500481/), [Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer](https://onco.cc/trials/nct03793179/), [Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct05096663/), [TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05955391/), [TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nsclc-3/), [the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib](https://onco.cc/trials/nct06370416/), [THIO Sequenced With Cemiplimab in Advanced NSCLC](https://onco.cc/trials/nct05208944/), [This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu](https://onco.cc/trials/nct06758401/), [TIME2](https://onco.cc/trials/time2/), [To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy](https://onco.cc/trials/nct04853342/), [To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N](https://onco.cc/trials/nct05442060/), [Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T](https://onco.cc/trials/nct04691817/), [TRACERx](https://onco.cc/trials/tracerx/), [Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC](https://onco.cc/trials/nct06456138/), [Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07246863/), [Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC](https://onco.cc/trials/nct07098988/), [Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor](https://onco.cc/trials/nct06472245/), [Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)](https://onco.cc/trials/nct06635824/), [TROPION-Lung01](https://onco.cc/trials/tropion-lung01/), [TROPION-Lung05](https://onco.cc/trials/tropion-lung05/), [TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma](https://onco.cc/trials/nct04969315/), [Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC](https://onco.cc/trials/nct04524689/), [TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases](https://onco.cc/trials/nct05948813/), [UKLS](https://onco.cc/trials/ukls/), [Using ctDNA to Determine Therapies for Lung Cancer](https://onco.cc/trials/nct04966663/), [Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases](https://onco.cc/trials/nct06683703/), [Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.](https://onco.cc/trials/nct06574347/), [Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI](https://onco.cc/trials/nct06343064/), [VIOLET](https://onco.cc/trials/violet/), [VISION (tepotinib)](https://onco.cc/trials/nct02864992/), [VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma](https://onco.cc/trials/nct03556228/), [Volrustomig Priming Regimens Exploratory Phase II Platform Study](https://onco.cc/trials/nct06448754/), [XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors](https://onco.cc/trials/nct07688577/), [YLST](https://onco.cc/trials/ylst/), [Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06933329/), [Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05502237/)
- people: [Alastair Greystoke](https://onco.cc/people/alastair-greystoke/), [Alexander Drilon](https://onco.cc/people/alexander-drilon/), [Alexis Cortot](https://onco.cc/people/alexis-cortot/), [Alfredo Addeo](https://onco.cc/people/alfredo-addeo/), [Alice T. Shaw](https://onco.cc/people/alice-shaw/), [Anne C. Chiang](https://onco.cc/people/anne-chiang/), [Ash A. Alizadeh](https://onco.cc/people/ash-alizadeh/), [Benjamin Besse](https://onco.cc/people/benjamin-besse/), [Benjamin Solomon](https://onco.cc/people/solomon-benjamin/), [Bob T. Li](https://onco.cc/people/bob-li/), [Byoung Chul Cho](https://onco.cc/people/cho-byoung-chul/), [C. S. Pramesh](https://onco.cc/people/pramesh-c-s/), [Caicun Zhou](https://onco.cc/people/zhou-caicun/), [Charles B. Simone II](https://onco.cc/people/charles-simone/), [Charles Swanton](https://onco.cc/people/charles-swanton/), [Charu Aggarwal](https://onco.cc/people/charu-aggarwal/), [Corinne Faivre-Finn](https://onco.cc/people/corinne-faivre-finn/), [D. Ross Camidge](https://onco.cc/people/ross-camidge/), [Dae Ho Lee](https://onco.cc/people/lee-dae-ho/), [Daniel A. Haber](https://onco.cc/people/daniel-haber/), [David Baldwin](https://onco.cc/people/david-baldwin/), [David Planchard](https://onco.cc/people/david-planchard/), [Denise R. Aberle](https://onco.cc/people/denise-aberle/), [Dong-Wan Kim](https://onco.cc/people/kim-dong-wan/), [Dongsheng Tu](https://onco.cc/people/tu-dongsheng/), [Enriqueta Felip](https://onco.cc/people/enriqueta-felip/), [Eric B. Haura](https://onco.cc/people/eric-haura/), [Everett E. Vokes](https://onco.cc/people/everett-vokes/), [Fabrice Barlesi](https://onco.cc/people/fabrice-barlesi/), [Ferdinandos Skoulidis](https://onco.cc/people/ferdinandos-skoulidis/), [Fiona Blackhall](https://onco.cc/people/fiona-blackhall/), [Frank McCormick](https://onco.cc/people/frank-mccormick/), [Gary Middleton](https://onco.cc/people/gary-middleton/), [Gregory J. Riely](https://onco.cc/people/gregory-riely/), [Harry J. de Koning](https://onco.cc/people/harry-de-koning/), [Haruhiko Fukuda](https://onco.cc/people/fukuda-haruhiko/), [Heather A. Wakelee](https://onco.cc/people/heather-wakelee/), [Helena A. Yu](https://onco.cc/people/helena-yu/), [Hidetoshi Hayashi](https://onco.cc/people/hidetoshi-hayashi/), [Hye Ryun Kim](https://onco.cc/people/kim-hye-ryun/), [Jean-Charles Soria](https://onco.cc/people/jean-charles-soria/), [Jeffrey D. Bradley](https://onco.cc/people/jeffrey-bradley/), [Jennifer S. Temel](https://onco.cc/people/jennifer-temel/), [Jie He](https://onco.cc/people/he-jie/), [Jie Wang](https://onco.cc/people/wang-jie-cams/), [Jin Seok Ahn](https://onco.cc/people/jin-seok-ahn/), [Joe Y. Chang](https://onco.cc/people/joe-chang/), [John Field](https://onco.cc/people/john-field/), [John V. Heymach](https://onco.cc/people/john-heymach/), [Jonathan Spicer](https://onco.cc/people/jonathan-spicer/), [Julie R. Brahmer](https://onco.cc/people/julie-brahmer/), [Jürgen Wolf](https://onco.cc/people/juergen-wolf/), [Justin F. Gainor](https://onco.cc/people/justin-gainor/), [Karen Kelly](https://onco.cc/people/karen-kelly/), [Karim Vermaelen](https://onco.cc/people/karim-vermaelen/), [Kathy S. Albain](https://onco.cc/people/kathy-albain/), [Keunchil Park](https://onco.cc/people/keunchil-park/), [Kevan M. Shokat](https://onco.cc/people/kevan-shokat/), [Koichi Goto](https://onco.cc/people/goto-koichi/), [Kumar Prabhash](https://onco.cc/people/prabhash-kumar/), [Lecia V. Sequist](https://onco.cc/people/lecia-sequist/), [Li Zhang](https://onco.cc/people/zhang-li-sysucc/), [Luis Paz-Ares](https://onco.cc/people/luis-paz-ares/), [Martin Reck](https://onco.cc/people/martin-reck/), [Martin Schuler](https://onco.cc/people/martin-schuler/), [Matthew Callister](https://onco.cc/people/matthew-callister/), [Matthew D. Hellmann](https://onco.cc/people/matthew-hellmann/), [Matthew Meyerson](https://onco.cc/people/matthew-meyerson/), [Matthias Guckenberger](https://onco.cc/people/matthias-guckenberger/), [Maximilian Diehn](https://onco.cc/people/maximilian-diehn/), [Michael Boyer](https://onco.cc/people/michael-boyer/), [Miriam Merad](https://onco.cc/people/miriam-merad/), [Myung-Ju Ahn](https://onco.cc/people/ahn-myung-ju/), [Natasha B. Leighl](https://onco.cc/people/natasha-leighl/), [Nathan A. Pennell](https://onco.cc/people/nathan-pennell/), [Nei-Min Chu](https://onco.cc/people/nei-min-chu/), [Nikolaus Rajewsky](https://onco.cc/people/nikolaus-rajewsky/), [Nobuyuki Yamamoto](https://onco.cc/people/nobuyuki-yamamoto/), [Óscar Gerardo Arrieta Rodríguez](https://onco.cc/people/oscar-arrieta-rodriguez/), [Pasi A. Jänne](https://onco.cc/people/pasi-janne/), [Patrick M. Forde](https://onco.cc/people/patrick-forde/), [Paul K. Paik](https://onco.cc/people/paul-paik/), [Philip Crosbie](https://onco.cc/people/philip-crosbie/), [Pilar Garrido](https://onco.cc/people/pilar-garrido/), [Primo N. Lara Jr.](https://onco.cc/people/primo-lara/), [Qing Zhou](https://onco.cc/people/qing-zhou/), [Ramaswamy Govindan](https://onco.cc/people/ramaswamy-govindan/), [Regina Barzilay](https://onco.cc/people/regina-barzilay/), [Reinhard Büttner](https://onco.cc/people/reinhard-buettner/), [Robert C. Doebele](https://onco.cc/people/robert-doebele/), [Robert D. Timmerman](https://onco.cc/people/robert-timmerman/), [Rolf A. Stahel](https://onco.cc/people/rolf-stahel/), [Roman Thomas](https://onco.cc/people/roman-thomas/), [Roy S. Herbst](https://onco.cc/people/roy-herbst/), [Sanjay Popat](https://onco.cc/people/sanjay-popat/), [Scott J. Antonia](https://onco.cc/people/scott-antonia/), [Se-Hoon Lee](https://onco.cc/people/lee-se-hoon/), [Shun Lu](https://onco.cc/people/lu-shun/), [Sir Richard Peto](https://onco.cc/people/richard-peto/), [Solange Peters](https://onco.cc/people/solange-peters/), [Stephen B. Baylin](https://onco.cc/people/stephen-baylin/), [Suresh S. Ramalingam](https://onco.cc/people/suresh-ramalingam/), [Suzanne L. Topalian](https://onco.cc/people/suzanne-topalian/), [Takashi Kohno](https://onco.cc/people/kohno-takashi/), [Tasuku Honjo](https://onco.cc/people/tasuku-honjo/), [Thomas J. Lynch Jr.](https://onco.cc/people/thomas-lynch/), [Timothy A. Chan](https://onco.cc/people/timothy-chan/), [Tina Cascone](https://onco.cc/people/tina-cascone/), [Tony S. K. Mok](https://onco.cc/people/tony-mok/), [Valerie W. Rusch](https://onco.cc/people/valerie-rusch/), [Vanita Noronha](https://onco.cc/people/noronha-vanita/), [Weimin Li](https://onco.cc/people/li-weimin/), [Wen-Zhao Zhong](https://onco.cc/people/wen-zhao-zhong/), [Wenfeng Fang](https://onco.cc/people/fang-wenfeng/), [Woong-Yang Park](https://onco.cc/people/park-woong-yang/), [Yi-Long Wu](https://onco.cc/people/wu-yi-long/), [Yosef Yarden](https://onco.cc/people/yosef-yarden/), [You Lu](https://onco.cc/people/lu-you/), [Yuankai Shi](https://onco.cc/people/shi-yuankai/), [Yuichiro Ohe](https://onco.cc/people/ohe-yuichiro/)
- key papers: [A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer](https://onco.cc/key-papers/paper-rimm-pd-l1-assay-comparison-jama-oncol-2017/), [Aaronson 1993: the EORTC QLQ-C30 quality of life questionnaire](https://onco.cc/key-papers/paper-aaronson-eortc-qlq-c30-jnci-1993/), [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M](https://onco.cc/key-papers/paper-thress-nat-med/), [Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain](https://onco.cc/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/), [Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/), [ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer](https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/), [ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-adaura-nejm-2020/), [Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)](https://onco.cc/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/), [Alectinib in resected ALK-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/), [Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/), [ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/), [Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014](https://onco.cc/key-papers/paper-allemani-concord-3-lancet-2018/), [Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers](https://onco.cc/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/), [Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer](https://onco.cc/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/), [ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors](https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/), [Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib](https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/), [Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels](https://onco.cc/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/), [Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042](https://onco.cc/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/), [Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer](https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/), [Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC](https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/), [Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab](https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/), [Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers](https://onco.cc/key-papers/paper-bray-globocan-2018-cacancer-2018/), [Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries](https://onco.cc/key-papers/paper-bray-globocan-2022-cacancer-2024/), [Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)](https://onco.cc/key-papers/paper-alta-jco-2017/), [Cancer Statistics, 2020: Report from National Cancer Registry Programme, India](https://onco.cc/key-papers/paper-mathur-ncrp-cancer-statistics-2020/), [Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer](https://onco.cc/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/), [CD74-NRG1 fusions in lung adenocarcinoma](https://onco.cc/key-papers/paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014/), [CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy](https://onco.cc/key-papers/paper-checkmate-017-nejm-2015/), [CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer](https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/), [CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer](https://onco.cc/key-papers/paper-checkmate-057-nejm-2015/), [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/), [Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials](https://onco.cc/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/), [Chen 2016: Cancer statistics in China, 2015](https://onco.cc/key-papers/paper-chen-cancer-statistics-china-2015-cacancer-2016/), [Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer](https://onco.cc/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/), [Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas](https://onco.cc/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/), [Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities](https://onco.cc/key-papers/paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015/), [CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug](https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/), [Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer](https://onco.cc/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/), [Comprehensive genomic characterization of squamous cell lung cancers](https://onco.cc/key-papers/paper-tcga-lung-squamous-nature-2012/), [Comprehensive genomic profiles of small cell lung cancer](https://onco.cc/key-papers/paper-george-sclc-genomic-profiles-nature-2015/), [Comprehensive molecular profiling of lung adenocarcinoma](https://onco.cc/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/), [Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes](https://onco.cc/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/), [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://onco.cc/key-papers/paper-archer-1050-lancet-oncol-2017/), [Detection of NRG1 gene fusions in solid tumors](https://onco.cc/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/), [Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status](https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/), [Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas](https://onco.cc/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/), [Doll and Hill 1950: the case-control study that tied smoking to lung cancer](https://onco.cc/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/), [DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer](https://onco.cc/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/), [Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease](https://onco.cc/key-papers/paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996/), [Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer](https://onco.cc/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/), [EGFR mutation and resistance of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/), [EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy](https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/), [EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes](https://onco.cc/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/), [Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers](https://onco.cc/key-papers/paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019/), [Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back](https://onco.cc/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/), [First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://onco.cc/key-papers/paper-ascend-4-lancet-2017/), [First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer](https://onco.cc/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/), [Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015](https://onco.cc/key-papers/paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017/), [Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer](https://onco.cc/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/), [FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-flaura-nejm-2018/), [FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer](https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/), [Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer](https://onco.cc/key-papers/paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010/), [Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma](https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/), [Genomic and evolutionary classification of lung cancer in never smokers](https://onco.cc/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/), [Genomic landscape of lung adenocarcinoma in East Asians](https://onco.cc/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/), [Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors](https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/), [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/), [Hollstein 1991: p53 mutations in human cancers](https://onco.cc/key-papers/paper-hollstein-p53-mutations-science-1991/), [Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer](https://onco.cc/key-papers/paper-soda-eml4-alk-fusion-nature-2007/), [Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations](https://onco.cc/key-papers/paper-archer-1050-os-jco-2018/), [Jemal 2011: Global cancer statistics (GLOBOCAN 2008)](https://onco.cc/key-papers/paper-jemal-global-cancer-statistics-2011-cacancer/), [KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off](https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/), [KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-keynote-010-lancet-2016/), [KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer](https://onco.cc/key-papers/paper-keynote-024-nejm-2016/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations](https://onco.cc/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/), [Lung adenocarcinoma promotion by air pollutants](https://onco.cc/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/), [Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group](https://onco.cc/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/), [MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling](https://onco.cc/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/), [MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression](https://onco.cc/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/), [MET exon 14 splicing alterations across tumour types and their sensitivity to MET inhibitors](https://onco.cc/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/), [Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing](https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/), [Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer](https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/), [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/), [Mutational signatures associated with tobacco smoking in human cancer](https://onco.cc/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/), [NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms](https://onco.cc/key-papers/paper-nelson-nejm-2020/), [NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer](https://onco.cc/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/), [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://onco.cc/key-papers/paper-checkmate-227-n-engl-j-med-2018/), [NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers](https://onco.cc/key-papers/paper-nlst-nejm-2011/), [Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC](https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/), [Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC](https://onco.cc/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/), [Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable](https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/), [PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer](https://onco.cc/key-papers/paper-pacific-nejm-2017/), [Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer](https://onco.cc/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/), [Parkin 2005: Global cancer statistics, 2002](https://onco.cc/key-papers/paper-parkin-global-cancer-statistics-2002-cacancer-2005/), [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://onco.cc/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/), [PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project](https://onco.cc/key-papers/paper-hirsch-j-thorac-oncol/), [PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project](https://onco.cc/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/), [Perioperative durvalumab for resectable non-small-cell lung cancer](https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/), [Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer](https://onco.cc/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/), [Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer](https://onco.cc/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/), [Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution](https://onco.cc/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/), [Ponsegromab for the Treatment of Cancer Cachexia](https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/), [Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies](https://onco.cc/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/), [Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F](https://onco.cc/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/), [Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer](https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/), [ROS1 rearrangements define a unique molecular class of lung cancers](https://onco.cc/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/), [SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization](https://onco.cc/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/), [Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial](https://onco.cc/key-papers/paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011/), [Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement](https://onco.cc/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/), [Siegel 2022: Cancer statistics, 2022](https://onco.cc/key-papers/paper-siegel-cancer-statistics-2022-cacancer-2022/), [Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies](https://onco.cc/key-papers/paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000/), [Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis](https://onco.cc/key-papers/paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013/), [STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma](https://onco.cc/key-papers/paper-kras-nsclc-cancer-discov-2018/), [Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer](https://onco.cc/key-papers/paper-sung-globocan-2020-cacancer-2021/), [Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer](https://onco.cc/key-papers/paper-temel-early-palliative-care-nejm-2010/), [The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer](https://onco.cc/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/), [The mortality of doctors in relation to their smoking habits; a preliminary report](https://onco.cc/key-papers/paper-doll-hill-mortality-of-doctors-smoking-bmj-1954/), [Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases](https://onco.cc/key-papers/paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/), [Torre 2015: Global cancer statistics, 2012](https://onco.cc/key-papers/paper-torre-global-cancer-statistics-2012-cacancer-2015/), [TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse](https://onco.cc/key-papers/paper-tracerx-evolution-nature-2023/), [TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse](https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/), [Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors](https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/), [Use of alternative medicine for cancer and its impact on survival](https://onco.cc/key-papers/paper-johnson-alternative-medicine-jnci-2018/), [Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs](https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/)
- journals: [Clinical lung cancer](https://onco.cc/journals/clinical-lung-cancer/), [Journal of Thoracic Oncology](https://onco.cc/journals/journal-of-thoracic-oncology/), [Lung cancer](https://onco.cc/journals/lung-cancer-journal/), [Thoracic cancer](https://onco.cc/journals/thoracic-cancer/), [Zhongguo fei ai za zhi](https://onco.cc/journals/chinese-journal-of-lung-cancer/)
- ideas: [A cheap old tablet to restore appetite](https://onco.cc/ideas/idea-bio2-low-dose-olanzapine-appetite/), [A clone report from blood at every treatment cycle](https://onco.cc/ideas/idea-bio1-ctdna-clone-report/), [A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards](https://onco.cc/ideas/idea-fund-flash-evidence-programme/), [A delivery-science moonshot for prevention we already own](https://onco.cc/ideas/idea-fund-prevention-moonshot/), [A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics](https://onco.cc/ideas/idea-moon-brain-delivery-platform/), [A standing platform for testing new drugs with radiotherapy](https://onco.cc/ideas/idea-tr2-rt-drug-platform/), [A test to tell true oligometastatic disease from hidden widespread spread](https://onco.cc/ideas/idea-bio2-oligometastatic-signature/), [Add a drug when the blood test turns, without stopping the one that works](https://onco.cc/ideas/idea-bio1-molecular-progression-add-on/), [Add the second drug on day one when the escape route is predictable](https://onco.cc/ideas/idea-bio1-upfront-bypass-combination/), [AI clears the normal lung screening scans so radiologists read only the suspicious ones](https://onco.cc/ideas/idea-prev-ldct-ai-negative-triage/), [AI malignancy scores to end repeat scans and biopsies for benign lung nodules](https://onco.cc/ideas/idea-prev-lung-nodule-ai-discharge/), [Automatic palliative care referral triggered by diagnosis, not by decline](https://onco.cc/ideas/idea-acc-automatic-early-palliative-triggers/), [Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models](https://onco.cc/ideas/idea-moon-closed-loop-adaptive-therapy/), [Bank three spatially separate tumour blocks from every resection](https://onco.cc/ideas/idea-bio1-multiregion-blocks-default/), [Biopsy the one lesion that is growing while the others shrink](https://onco.cc/ideas/idea-bio1-outlier-lesion-biopsy/), [Block the complement signal that recruits tumour-protecting cells](https://onco.cc/ideas/idea-bio2-complement-c5ar-blockade/), [Blunt the inflammation that wakes sleeping cancer cells](https://onco.cc/ideas/idea-bio2-il1-awakening-blockade/), [Borrow from past control arms to shrink the control group in phase 3](https://onco.cc/ideas/idea-tr1-bayesian-borrowing-smaller-controls/), [Brain metastases included by default in every solid-tumour trial](https://onco.cc/ideas/idea-tr1-brain-mets-default-included/), [Build a human model of the barrier that guards the brain fluid](https://onco.cc/ideas/idea-bio2-blood-csf-barrier-model/), [Burden-weighted portfolio targets for every major cancer funder](https://onco.cc/ideas/idea-fund-burden-weighted-portfolio/), [Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial](https://onco.cc/ideas/idea-nl-diet-covariates-io-trials/), [Catch wasting early with a smart scale and a step counter](https://onco.cc/ideas/idea-bio2-remote-weight-step-monitoring/), [CD8 PET to stop or switch immunotherapy early](https://onco.cc/ideas/idea-cd8-pet-io/), [Combine the new anti-wasting antibody with exercise and protein](https://onco.cc/ideas/idea-bio2-gdf15-plus-exercise/), [Competing sponsors share one control arm in the same indication](https://onco.cc/ideas/idea-tr1-shared-control-arms-across-sponsors/), [Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide](https://onco.cc/ideas/idea-reg-olanzapine-cachexia-global-confirmation/), [Confirm or refute the harm of antioxidant supplements during chemotherapy](https://onco.cc/ideas/idea-nl-antioxidant-supplement-harm-confirmation/), [Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live](https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/), [ctDNA-guided dose holidays for lung cancer targeted therapy](https://onco.cc/ideas/idea-bio1-ctdna-adaptive-tki/), [Decide who is screened for lung cancer by individual risk, not by pack-years](https://onco.cc/ideas/idea-lung-screening-eligibility-by-risk-not-pack-years/), [Dedicated cohorts for patients with performance status 2 in first-line trials](https://onco.cc/ideas/idea-tr1-ecog-2-dedicated-cohorts/), [Detect tumours changing cell type from RNA in the blood](https://onco.cc/ideas/idea-bio1-cfrna-plasticity-tracking/), [Evaluate clean-air policies using lung cancer in never-smokers](https://onco.cc/ideas/idea-prev-clean-air-never-smoker-endpoints/), [Every lung screening visit includes stop-smoking medicine, opt-out](https://onco.cc/ideas/idea-prev-opt-out-cessation-in-lung-screening/), [Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway](https://onco.cc/ideas/idea-prev-opportunistic-ct-ai-registry/), [Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable](https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/), [Get the one approved appetite drug licensed beyond a single country](https://onco.cc/ideas/idea-bio2-anamorelin-access/), [Give immunotherapy in the morning](https://onco.cc/ideas/idea-chronotherapy-immunotherapy/), [Intercept cancer at the field stage](https://onco.cc/ideas/idea-field-interception/), [Kill drug-tolerant persisters through ferroptosis](https://onco.cc/ideas/idea-ferroptosis-persisters/), [Look for the resistant sub-population before the first dose](https://onco.cc/ideas/idea-bio1-baseline-ultradeep-resistant-clones/), [Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers](https://onco.cc/ideas/idea-prev-lung-screening-risk-model-eligibility/), [Make bespoke mouse cancer models in weeks with in vivo gene editing](https://onco.cc/ideas/idea-bio1-somatic-crispr-gemms/), [Make cigarettes non-addictive by capping their nicotine](https://onco.cc/ideas/idea-prev-very-low-nicotine-mandate/), [Make resistance a diagnosis: sequence at every progression and choose the next line from what the tumour became](https://onco.cc/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/), [Mandatory radon testing when homes are sold, with subsidised mitigation](https://onco.cc/ideas/idea-prev-radon-testing-at-property-sale/), [Map metabolic dependencies in the patient, not the dish](https://onco.cc/ideas/idea-metabolic-vulnerability-mapping/), [Measure brain metastasis prevention as a primary endpoint, not as a secondary one](https://onco.cc/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/), [Microbiome transplant as a routine immunotherapy adjunct](https://onco.cc/ideas/idea-microbiome-io-fmt/), [Molecular indolence classifiers bundled with every screening programme](https://onco.cc/ideas/idea-moon-indolence-classifiers-with-screening/), [Pathologists order genomic profiling automatically at diagnosis of advanced cancer](https://onco.cc/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/), [Pause a failed drug so the tumour becomes sensitive to it again](https://onco.cc/ideas/idea-bio1-drug-holiday-resensitisation/), [Pre-surgery platform trials that test combinations on pathological response in months](https://onco.cc/ideas/idea-tr2-neoadjuvant-combo-platform/), [Prevention trials aimed only at brain metastasis](https://onco.cc/ideas/idea-bio2-brain-met-prevention-trials/), [Protect hearing from cisplatin in adults as we now do in children](https://onco.cc/ideas/idea-moon-hearing-protection-cisplatin/), [Protect the gut flora of patients about to start immunotherapy](https://onco.cc/ideas/idea-bio2-antibiotic-stewardship-io/), [Publish the four numbers the NHS lung cancer pathway does not currently measure: reflex testing rate, genomic turnaround, surgical access and a lung-specific waiting time in every nation](https://onco.cc/ideas/idea-lung-uk-screening-testing-and-access-gaps/), [Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list](https://onco.cc/ideas/idea-prev-cytisine-essential-medicine/), [Randomise a cheap antihistamine alongside immunotherapy](https://onco.cc/ideas/idea-reg-antihistamine-plus-io-trial/), [Randomised trials of stopping immunotherapy after one year versus continuing](https://onco.cc/ideas/idea-tr1-immunotherapy-stop-trials/), [Re-test the metastasis, not the old primary, before every change of treatment](https://onco.cc/ideas/idea-bio1-rebiopsy-before-switch/), [Select cachexia trial patients by the hormone driving their wasting](https://onco.cc/ideas/idea-bio2-gdf15-stratified-enrolment/), [Select patients for cell therapy by whether their tumour holds reactive T cells](https://onco.cc/ideas/idea-bio2-til-reactivity-selection/), [Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy](https://onco.cc/ideas/idea-bio1-apobec-inhibitor-adjunct/), [Smoke-free generation laws with a built-in evaluation across countries](https://onco.cc/ideas/idea-prev-smokefree-generation-evaluation/), [Social impact bonds for cancer prevention, repaid from avoided treatment costs](https://onco.cc/ideas/idea-fund-social-impact-bonds-prevention/), [Standing reflex biomarker panels per tumour type, run without an oncologist's order](https://onco.cc/ideas/idea-acc-reflex-biomarker-panels-by-tumour/), [Switch drugs at maximum response, not at relapse](https://onco.cc/ideas/idea-bio1-first-strike-second-strike/), [Take lung screening scanners to supermarket car parks in the poorest areas](https://onco.cc/ideas/idea-prev-mobile-lung-screening-deprived-areas/), [Test a high-fibre diet as an immunotherapy adjunct](https://onco.cc/ideas/idea-bio2-fibre-diet-io-trial/), [Test alternating drug schedules against giving both drugs at once](https://onco.cc/ideas/idea-tr2-alternating-vs-concurrent/), [Test intermittent dosing of targeted drugs to delay resistance, with honest priors](https://onco.cc/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/), [Test protein and resistance training during immunotherapy](https://onco.cc/ideas/idea-bio2-protein-plus-training-during-io/), [Treat brain metastases as a disease with its own trials programme](https://onco.cc/ideas/idea-fund-brain-metastases-programme/), [Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles](https://onco.cc/ideas/idea-moon-cachexia-as-treatable-disease/), [Treat cachexia before it starts](https://onco.cc/ideas/idea-cachexia-gdf15-prevention/), [Treat immunotherapy side-effects without wiping out the response](https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/), [Treat lung cancer in never-smokers as its own disease, with its own detection programme](https://onco.cc/ideas/idea-lung-never-smoker-disease-its-own-programme/), [Treat the deprivation gradient in lung cancer as a defect in delivery that can be fixed and measured](https://onco.cc/ideas/idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery/), [TROP2 PET to choose and sequence TROP2 ADCs](https://onco.cc/ideas/idea-trop2-pet-selection/), [Turn a brake back on: drugs that reactivate the PP2A phosphatase](https://onco.cc/ideas/idea-bio1-pp2a-activators/), [Unmask hidden antigens with a short epigenetic course before immunotherapy](https://onco.cc/ideas/idea-bio2-epigenetic-priming-cold-tumours/), [Use a blood test at six weeks to decide whether to keep going](https://onco.cc/ideas/idea-bio2-ctdna-six-week-io-switch/), [Use a hypoxia scan to pick patients for adenosine-pathway drugs](https://onco.cc/ideas/idea-bio2-hypoxia-guided-adenosine/), [Use LET, RBE and alpha/beta to decide when protons beat IMRT](https://onco.cc/ideas/idea-bio2-let-rbe-ab-selects-protons/), [Use the brain's own transport door to carry antibody drugs across](https://onco.cc/ideas/idea-bio2-transferrin-shuttle-adc/), [Use tumour DNA in blood to decide when to pause treatment in metastatic cancer](https://onco.cc/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/), [Video palliative care as an equivalent default option for patients far from a team](https://onco.cc/ideas/idea-acc-tele-palliative-care-default/), [Watch the immune system's response in the blood three weeks in](https://onco.cc/ideas/idea-bio2-tcr-repertoire-early-readout/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [AI that is built but not validated or deployed](https://onco.cc/bottlenecks/b-ai-validation/), [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Knowledge reaches practice too slowly](https://onco.cc/bottlenecks/b-knowledge-diffusion/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/), [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/), [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Overdiagnosis and false alarms](https://onco.cc/bottlenecks/b-overdiagnosis/), [Pain relief and palliative care are unavailable to most](https://onco.cc/bottlenecks/b-palliative/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/), [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/), [Tumour heterogeneity and clonal evolution](https://onco.cc/bottlenecks/b-tumor-heterogeneity/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- collections: [Australia's national cancer screening programs](https://onco.cc/collections/australia-cancer-screening-programs/), [LUNGevity Foundation (and GO2 for Lung Cancer)](https://onco.cc/collections/lungevity/), [NHS cancer screening programmes](https://onco.cc/collections/nhs-cancer-screening-programmes/)

---
JSON: https://onco.cc/api/v1/entities/nsclc.json